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more and more difficult to treat due to the dwindling number of antibiotics available to treat such
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2 explores the current therapy regime for combating tuberculosis and expresses the need for novel
agents in this arena. It also shows how current medicinal chemistry techniques are being utilized to
develop a novel class of potential anti-tuberculosis agents with novel mechanisms of action. Chapter 3
discusses the treatment of gram-negative bacterial infections with novel hybrid antimicrobial agents.
These agents afford current antimicrobial agents, which have difficulty penetrating the gram-negative cell
wall, a way into the gram-negative cell in order to exert their intended mechanism of action. This chapter
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the work detailed in the dissertation; as well as future directions that will help further the scope of these
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ABSTRACT
There is an ever increasing need to develop new antimicrobial agents with novel
mechanisms of action. These new agents will help to combat the steady rise of antibioticresistant bacteria which are becoming more and more difficult to treat due to the
dwindling number of antibiotics available to treat such organisms. This body of work
brings to light the many ways in which medicinal chemistry plays a vital role in the
discovery of novel antimicrobial agents. Chapter 1 is an introduction into antimicrobial
agents. It provides a brief history of the discovery of antimicrobial agents, and delves
into reasons why new agents are urgently needed. It also examines the recent
antimicrobial agents approved by the Food and Drug Administration for use in the United
States, and looks into the current antimicrobial drug pipeline. Chapter 2 explores the
current therapy regime for combating tuberculosis and expresses the need for novel
agents in this arena. It also shows how current medicinal chemistry techniques are being
utilized to develop a novel class of potential anti-tuberculosis agents with novel
mechanisms of action. Chapter 3 discusses the treatment of gram-negative bacterial
infections with novel hybrid antimicrobial agents. These agents afford current
antimicrobial agents, which have difficulty penetrating the gram-negative cell wall, a way
into the gram-negative cell in order to exert their intended mechanism of action. This
chapter explores the rationale and design behind the making of such agents. Chapter 4
provides an overview of the work detailed in the dissertation; as well as future directions
that will help further the scope of these projects.
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CHAPTER 1: INTRODUCTION
Introduction to Antibacterial Agents
Infectious diseases have been one of the greatest blights in the history of
humanity.1 It was not until the discovery of the first antibacterial agent in the 1930s that
a glimmer of hope was seen. That agent was Prontosil, and it was discovered by Gerhard
Domagk in 1935.1-3 Prontosil was later found to be a prodrug that was metabolized in
vivo to its active metabolite sulfanilamide (Figure 1.1).4 Prontosil was the first of the
“sulfa” drugs discovered, and its discovery ushered in the era of antibiotics.
Antibacterial agents, or antibiotics, are a class of a much larger group of
compounds called antimicrobial agents. Antibiotics used to refer to only naturally
occurring molecules produced by a variety of microorganisms.5 However, the term has
evolved to include man-made synthetic compounds as well.6 Antibiotics can be broken
down into four distinct classes based upon their mechanism of action. Those four classes
are (1) the agents that inhibit bacterial cell wall biosynthesis, (2) the agents that inhibit
protein biosynthesis, (3) the agents that inhibit deoxyribonucleic acid (DNA) or
ribonucleic acid (RNA) synthesis, and (4) the agents that inhibit folate synthesis.6
Inhibitors of Bacterial Cell Wall Biosynthesis
The bacterial cell wall plays a vital role in the survival and proliferation of the
bacteria. There are also substantial differences between the mammalian cell wall and the
bacterial cell wall, thus creating an attractive target for bacterial chemotherapy. This
class of antibiotics contains two families of compounds that act upon various targets
within the biosynthetic cascade of cell wall formation. Those two families are the βlactams and the glycopeptides.
β-lactams
This family of compounds is comprised of four groups of molecules: (1) the
penicillins, (2) the cephalosporins, (3) the carbapenems, and (4) the monobactams (Figure
1.2). This family of compounds all act via the same mechanism of action, and that is by
binding and inhibiting the penicillin binding proteins (PBPs); more specifically they
inhibit peptidoglycan transpeptidase causing lysis and cell death.1,6 The core structure of
this family consists of an β-lactam core, which contains a carbonyl lactam structure this is
essential for the activity of these molecules.1,7 To differentiate the various groups of
molecules within this family, one must look at the ring that is fused to the β-lactam core.1
The first group of molecules is the penicillins, and they contain a saturated pentacyclic
ring system fused to the core ring structure.
The penicillins have been greatly modified from the initial compound isolated,
Penicillin G. These modifications occur off of the carbonyl position on the amide side
1

O
H2 N

S

NH 2
N

O

NH2
O

in vivo

N

O
H2 N
Sulfanilamide

Protosil

Figure 1.1:

R

Activation of Prontosil to Sulfanilamide

O
H H
S
HN
O

R

N

O
H H
HN
O

CO 2H

Penicillins

Figure 1.2:

NH2

S

N

HO
H
R
CO2 H

H H
S
O

Cephalosporins

R

CO 2H

Carbapenems

R

O
H
HN
O

N

R

Monobactams

General Structures of the Four Classes of β-Lactam Antibiotics

2

chain.8 The modifications have been made in an effort to improve the potency, oral
bioavailability, antibacterial spectrum of activity, and decrease sensitivity to βlactamases.9
The next group of molecules in this family are the cephalosporins. This group is
recognized by its unsaturated hexacyclic ring structure attached to the azetidinone core.
The cephalosporins are the most widely prescribed and largest-selling group of the βlactams.6 Since their discovery in the 1960s, thousands of derivatives have been
synthesized in an effort to increase the spectrum of activity and decrease the β-lactamase
susceptibility of this group of compounds.1,5
The carbapenems are recognized by their unsaturated pentacyclic ring structure
attached to the core β-lactam structure. These molecules exhibit a broad spectrum of
activity, but have low oral bioavailability.1,5,10,11 This group of molecules possesses an
added benefit of being resistant to most β-lactamases, thus increasing their potency and
spectrum of action.6,9
The final group of molecules in this family are the monobactams. These
molecules are very easy to identify due to the fact that they only possess azetidinone core
with no other fused ring system. These compounds are only active against gram negative
pathogens, with good activity against P. aeruginosa.6,12-16 These molecules have a
similar mechanism of action as the other β-lactam antibiotics, but they possess a
specificity for PBP3 and can be complementary to other β-lactams.6,9
Glycopeptides and Lipoglycopeptides
This family of compounds was first discovered with vancomycin in 1956, and
was later expanded to include lipoglycopeptides by Lancini in 1989 after the discovery of
teicoplanin in 1978 (Figure 1.3).1,17 The mechanism of action of the family differs
slightly from that of the β-lactams. The glycopeptides are able to cross the bacterial cell
wall of gram-positive bacteria and bind to the terminal D-ala-D-ala dipeptide of the
peptidoglycan precursor. The steric hindrance caused by these molecules blocks two key
enzymatic reactions of peptidoglycan synthesis, transglycosylation and transpeptidation,
ultimately causing inhibition of growth and death.1 These compounds are reserved as
drugs of last resort due to their excellent activity against gram-positive bacteria,
especially methicillin-resistant Staphylococcus aureus (MRSA).18
Inhibitors of Protein Biosynthesis
This class of compounds exert their antibacterial action by blocking one or more
of the steps in protein biosynthesis that occur on either the 30S or 50S subunits of the
bacterial ribosome. There are a number of families of molecules that make up this family
including the macrolides, lincosamides, streptogramins, oxazolidinones,
aminoglycosides, and tetracyclines.6 However, the major families that compose this
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family are the aminoglycosides, macrolides, and tetracylines. Therefore these three
groups will be discussed further in this section.
Aminoglycosides
This family of molecules all contain a pharmacophoric 1,3-diaminoinositol
moiety (Figure 1.4).5 This family of compounds acts on the 30S ribosomal subunit, more
specifically the 16S ribosomal ribonucleic acid (rRNA).19 Upon binding, they impair the
proofreading ability of the ribosome; therefore causing mistranslation of RNA templates
and consequent selection of wrong amino acids leading to the formation of nonsense
proteins.5 This prevents the proper joining of the 30S and 50S ribosomal subunits
leading to the inhibition of protein synthesis. These antibiotics are structurally diverse,
and it has been suggested that the name of this family change to aminocyclitols in order
to encompass the wide array of structures found in this class.20 These agents alone show
potent activity against gram-negative bacteria, but lack potent activity against most grampositive bacteria. However, they are used in combination with β-lactams to treat some
enterococcal infections.6,8
Macrolides
The name for this family of molecules is derived from the large lactone, cyclic
ester, ring structure found in each of these compounds (Figure 1.5).5 These compounds
exert their antibacterial action by binding reversibly to the 50S ribosomal subunit and
preventing protein elongation by blocking peptidyltransferase from forming peptide
bonds between amino acids.21,22 These agents also block the assembly of the 50S
ribosomal subunit through an interaction with the 23S rRNA.23 A new derivation of this
family has recently been discovered and approved for use in the United States, and they
are the ketolides. In this subfamily, the 3-OH is oxidized to a ketone, thus removing the
site of attachment of the cladinose sugar.24 This entire family of agents is considered
broad-spectrum antibiotics, especially as newer agents continue to be developed.
Tetracyclines
This family consists of molecules with a highly functionalized and partially
reduced naphthacene (four linearly fused six-membered rings) ring system (Figure 1.6).5
These agents work at the 30S ribosomal subunit and block the binding of incoming
aminoacyl-transfer ribonucleic acid (t-RNA) to the A site resulting in termination of
peptide chain elongation.5,6 This family of antibiotics are classified as broad-spectrum.
However, due to their adverse side effects (staining of teeth and impairment of bone
structure development) they are rarely the drug of choice for treatment, especially for
children.5,25
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Inhibitors of DNA and RNA Synthesis
This class of antibiotics works on one of three targets: DNA gyrase,
topoisomerase IV, or DNA-directed RNA polymerase. There are two families of
antibiotics included within this class, and those are the quinolones and the rifamycins.
The activity of the quinolones (Figure 1.7) is derived from their inhibition of DNA gyrase
and topoisomerase IV.5 While DNA gyrase and topoisomerase IV have similar
mechanisms of action, the difference is the fact that DNA gyrase is more important for
gram-negative organisms and topoisomerase IV is more important for gram-positive
organisms.9,26 The quinolones work by binding to DNA gyrase or topoisomerase IV and
preventing the supercoiling of DNA, thereby inhibiting synthesis of DNA.6 The
quinolones were not widely used until the discovery of the fluoroquinolones in the
1980s.27 There are currently four generations of quinolones that have been developed
and are in clinical use.
The rifamycin family of antibiotics works on DNA-directed RNA polymerase.
These agents bind to the β-subunit of DNA-directed RNA polymerase and inhibit the
initiation of chain formation in RNA synthesis.6 Rifamycin is a natural product with
several natural analogs, but three semisynthetic analogs have since been synthesized.
Those agents are rifampin (Figure 1.8), rifabutin, and rifapentine. These agents are frontline agents in the treatment of tuberculosis.
Inhibitors of Folate Synthesis
Folate is critical to the survival of all living organisms.28 It plays a role in DNA
synthesis by serving in the transfer of methyl, formyl, and other single-carbon fragments
in the biosynthesis of purine nucleotides.29 Humans and bacteria obtain folate via
different routes. Humans obtain folate through their diet, while bacteria synthesis folate
through the folate biosynthetic pathway. This difference makes the folate biosynthetic
pathway a very attractive drug target.28 There are two enzymes in this pathway that are
currently targeted by antibacterial agents: dihydropteroate synthesis (DHPS) and
dihydrofolate reductase (DHFR). The family of agents that act on DHPS is the
sulfonamides. DHFR is acted upon by a single agent, and that is trimethoprim.5
Sulfonamides

The sulfonamides work by inhibiting DHPS, which catalyses the conversion of paminobenzoic acid (PABA) to dihydroteroate.30,31 Due to resistance issues, most of the
originally developed sulfonamide drugs are no longer in use as a monotherapy.
However, there are some still in use for acne and urinary tract infections. The most
commonly used drug is in this class is sulfamethoxazole (Figure 1.9). This agent is often
used in combination with trimethoprim, which expands it antibacterial spectrum and
reduces the potential for the development of drug resistance.9
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Trimethoprim

Trimethoprim works by inhibiting DHFR, which converts dihydrofolate into
tetrahydrofolate.32 This enzyme is found in humans as well as bacteria, thus it is
important that trimethoprim selectively inhibit the bacterial form of the enzyme. It is
found that trimethoprim inhibits bacterial DHFR at a much lower concentration than the
human DHFR, thus providing the basis for its selectivity.5 While trimethoprim (Figure
1.10) is often used in combination with sulfamethoxazole, it can also be utilized as a
standalone agent.33
The Need for Novel Antibacterial Agents

The prevalence of drug resistant bacteria is growing at an alarming rate in both
developing and developed countries.34 From this statement alone, it should be clear that
the need for the development of novel antibacterial agents is of utmost importance. In the
current antibacterial drug pipeline, there is only a miniscule glimmer of hope.34-38 This
rapid increase in resistant bacteria coupled with the slow development of novel agents
has lead some experts to call this time the “dawn of the post-antibiotic era.”39-41
There exists a perpetual need for new antibiotics. Most drugs will be just as
effective in the future as they are today, but that is not the case with antibiotics.
Eventually, the inevitable rise of resistance will erode the utility of today’s antibiotics.6,36
There are three factors that intensify this supply problem by discouraging antibiotic
development.42 First, antibiotics are used in smaller quantities than other drugs. The
standard antibiotic course lasts only weeks compared to treatment for chronic illness
which can last a lifetime. Therefore, antibiotics yield lower revenues than most drugs.
Second, the use of newly approved antibiotics is often limited to serious bacterial
infections. The third reason is an increase in regulatory requirements to get a drug
licensed, which makes clinical trials cost prohibitive. However, most newly approved
drugs can be prescribed to all who may benefit from their use. These factors ultimately
result in this quandary: Resistance is on the rise while antibiotic discovery and
development are on the decline.36,43,44
Three classes of antibiotic-resistant pathogens are emerging as major threats to
public health. The first pathogen of concern is MRSA. It is estimated that MRSA is
responsible for approximately 19,000 deaths per year in the United States. The rising
prevalence of MRSA increases the likelihood that vancomycin-resistant Staphylococcus
aureus (VRSA), which is just as deadly as MRSA but more challenging to treat, will
become a major concern in hospitals.45,46 The second class of pathogens are multidrugresistant (MDR) and pandrug-resistant (PDR) gram-negative bacteria. These bacteria
may be less prevalent than MRSA, but they pose a severe risk of infections that are truly
untreatable. These strains of Acinetobacter baumannii, Esherichia coli, Klebsiella
pneumonia, and Pseudomonas aeruginosa are resistant to some (MDR) or all (PDR) of
the antibiotics used to treat gram-negative bacteria: penicillins, cephalosporins,
carbamenems, monobactams, quinolones, aminoglycosides, tetracyclines, and
11
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polymixins.47 The third class of pathogens are MDR and extensively drug-resistant
(XDR) strains of Mycobacterium tuberculosis. These strains are an ever increasing threat
in developing nations.48 MDR-TB treatments requires a 2-year course of antibiotics with
serious side effects; XDR-TB is even more difficult to treat and often fatal.49
The number of new antibiotic agents approved by the Food and Drug
Administration (FDA) has fallen steadily since 1980.39 It is also pertinent to note that
during that time 75 percent of the drugs approved were in two classes, beta-lactams and
quinolones. Between 1935 and 1968 there were 14 classes of antibiotics introduced for
human used; since then, only five have been introduced. Those five classes are; the
oxazolidinones, lipopeptides, glycylcyclins, pleuromutilins, and mupirocin.39 While most
new antibiotics come from existing classes, there is now more diversity within these
classes. Also, these new agents may be more effective and safer than earlier drugs in
their class.50
New Antibiotics

The FDA is the approving body for new antibiotics in the United States. Once a
new drug has the approval of the FDA, it can be sold for use in the United States. Since
1998, the FDA has approved a number of new antibiotics. However, only a limited
number of these agents possess a novel mechanism of action. Having new antibiotics
approved for use is a great thing, but those antibiotics which utilize the same mechanism
of action as previously approved drugs always run the risk of increasing the rate of
resistance. Drugs possessing a novel mechanism of action are greatly needed to help
alleviate this burden.
Recently Approved Antibiotics
This section contains a list and description of each new antibacterial agent that
has been approved since 2000.39
Linezolid

This drug is sold under the brand name Zyvox (Figure 1.11). It was approved for
use by the FDA in 2000. Sales of this drug are now over $1 billion dollars per year. It is
approved to treat VRE infections, as well as hospital- and community-acquired
pneumonia and cSSTI caused by gram-positive organisms; including methicillin-resistant
Staphylococcus aureus (MRSA). This is the first and only commercially available drug
in the oxazolidinone class. This is a new class of antibiotics which acts by inhibiting
protein synthesis in a novel way compared to currently known mechanisms of other
antibiotics.
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Cefditoren

Sold under the brand name Spectracef, it was approved for use by the FDA in
2001 (Figure 1.12). It is approved for the treatment of bronchitis and communityacquired pneumonia caused by drug-susceptible gram-positive and gram-negative
organisms. It is also used to treat uncomplicated skin- and soft-tissue infections caused
by MSSA, as well as pharyngitis and tonsillitis caused by Streptococcus pyogenes. This
drug is a third generation cephalosporin antibiotic.
Ertapenem

This drug is sold under the brand name Invanz (Figure 1.13). It was approved by
the FDA in 2001. It can be used to treat intra-abdominal infections, community-acquired
pneumonia, urinary tract infections, cSSTI, and acute pelvic infections caused by grampositive and gram-negative organisms. However, it lacks activity against Pseudomonas
aeruginosa. This drug belongs to the carbapenem class of antibiotics.
Gemifloxacin

Sold under the brand name Factive (Figure 1.14), it was approved for use by the
FDA in 2003. It is approved for the treatment of community-acquired pneumonia and
bronchitis caused by gram-positive and gram-negative organisms; including multi-drug
resistant Streptococcus pneumoniae. This drug belongs to the fluoroquinolone class of
antibiotics.
Daptomycin

This drug is sold under the brand name Cubicin (Figure 1.15). It was approved
for use by the FDA in 2003. Sales of this drug have reached over $600 million dollars
per year in the United States. It is approved for the treatment of cSSTI and bacteremia
caused by gram-positive bacteria; including MRSA. Daptomycin belongs to the new
lipopeptide class of antibiotics. It presents a novel mechanism of action by disrupting
multiple aspects of bacterial cell membrane function.
Telithromycin

Sold under the brand name Ketek, telithromycin (Figure 1.16) was approved for
use by the FDA in 2004. It is approved for use in the treatment of community-acquired
pneumonia caused by gram-positive and gram-negative bacteria; including multi-drug
resistant strains of Streptococcus pneumoniae. When first approved by the FDA,
telithromycin was approved for use in treating numerous bacterial infections. However,
due to safety issues with the drug, the FDA removed its approval to treat some infections
and issued a black box warning for the drug in 2007 stating that patients with myasthenia
gravis should not take this drug.51 Telithromycin is the first ketolide antibiotic to enter
clinical use.
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Figure 1.12: Structure of Cefditoren
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Figure 1.13: Structure of Ertapenem
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Figure 1.14: Structure of Gemifloxacin
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Figure 1.15: Structure of Daptomycin
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Figure 1.16: Structure of Telithromycin
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Tigecycline

Tigecycline is sold under the brand name Tygacil (Figure 1.17). It was approved
by the FDA in 2005. It is used for the treatment of cSSTI and intra-abdominal infections
caused by gram-positive and gram-negative bacteria; including MRSA. This agent
belongs to the recently discovered glycylcycline subclass of tetracycline antibiotics.
Retapamulin

This drug is sold under the brand name Altabax (Figure 1.18). It was approved
for use by the FDA in 2007. This agent is only approved for topical use in the treatment
of impetigo caused by gram-positive infections. This drug is the first drug in the new
class of pleuromutilin antibiotics to be approved for human use.
Doripenem

Sold under the brand name Doribax, Doripenem (Figure 1.19) was approved for
use by the FDA in 2007. It is approved for the treatment of intra-abdominal infections
and urinary tract infections caused by gram-positive and gram-negative bacteria. This
agent is an ultra-broad spectrum injectable antibiotic belonging to the carbapenem class
of antibiotics. It shows very good efficacy against Pseudomonas aeruginosa.
Telavancin

Telavancin is sold under the brand name Vibativ (Figure 1.20). It was approved
for use by the FDA in 2009. It is approved for the treatment of cSSTI caused by grampositive bacteria; including MRSA. Telavancin is a member of the lipoglycopeptide
class of antibiotics, and is a synthetic derivative of vancomycin.
Antibiotics in the Pipeline: Gram-Positive
This section contains information about agents that are currently in the pipeline
for the treatment of gram-positive bacteria.35 In the current antibiotic pipeline, there are
numerous potentially new agents that can be utilized to treat bacterial infections. The
majority of those agents are aimed at treating infections caused by gram-positive
organisms. A high percentage of these agents build upon previously known antibiotic
groups. However, there are a handful of novel agents coming through the pipeline which
have novel scaffolds and/or novel mechanisms of action.
Oritavancin

Oritavancin (Figure 1.21) is in the final stages of approval by the FDA. It has
been temporarily rejected by the ruling body pending further clinical investigations into
its safety profile. It belongs to the glycopeptides family of antibiotics, and is pending
approval for the treatment of cSSTI.
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Telavancin
Figure 1.20: Structure of Telavancin
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Figure 1.21: Structure of Oritavancin
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Iclaprim

This agent is currently under review by the FDA, but the FDA has ruled that it is
not approvable in its current form. Iclaprim (Figure 1.22) is a 2,4-Diaminopyrimidine
(structurally related to trimethoprim) which acts as a dihydrofolate reductase inhibitor. It
is pending approval for the treatment of cSSTI.
Ceftobiprole

Ceftobiprole (Figure 1.23) is currently under review by the FDA, but the FDA has
deemed that further clinical-site audits are necessary before a final review can be
obtained. Ceftobiprole is a fifth-generation cephalosporin. This agent is being reviewed
for the treatment of cSSTI; including diabetic foot infections. It is also currently
undergoing Phase 3 clinical trials for the treatment of hospital-acquired pneumonia and
severe community-acquired pneumonia. This agent is notable for its activity against
MRSA.
Cethromycin

This agent is currently under review by the FDA (Figure 1.24). The FDA has
deemed that further clinical site studies are needed in order for an approval to be
obtained. This agent belongs to the macrolide subclass of antibiotics known as ketolides.
It is being investigated for effectiveness against community-acquired pneumonia and
against biodefense pathogens such as anthrax, plague, tularemia, and melloidosis.
Ceftaroline

This has completed Phase 3 clinical trials for the treatment of cSSTI and is
currently in Phase 3 trials for the treatment of community-acquired pneumonia. It is a
fifth-generation cephalosporin (Figure 1.25). This agent also shows promising activity
against MRSA.
Fidaxomicin

This agent is currently undergoing Phase 3 clinical trials for the treatment of
Clostridium difficile-associated diseases (Figure 1.26). This agent represents a new class
of antibiotics for the treatment of these diseases; RNA polymerase inhibitor.
Ramoplanin

This agent is currently undergoing Phase 2/3 trials for the treatment of
Clostridium difficile-associated diseases resistant to vancomycin/metronidazole (Figure
1.27). It belongs to the glycolipdepsipeptide class of antibiotics and works by inhibiting
cell wall biosynthesis. It has been fast-tracked by the FDA in hopes to expedite its
approval.
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Figure 1.24: Structure of Cethromycin
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Figure 1.25: Structure of Ceftaroline
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Fidaxomicin

Figure 1.26: Structure of Fidaxomicin
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Figure 1.27: Structure of Ramoplanin
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Pagibaximab

Pagibaximab is a chimeric monoclonal antibody against lipoteichoic acid. This
agent represents an agent with a novel mechanism of action in the treatment of bacterial
infections. It is currently undergoing Phase 2b/3 clinical trials as a staphylococcal
prophylaxis in very low birth weight neonates.
Phase 2 Completed

All of the agents discussed in the section have all completed Phase 2 clinical
trials, but have not yet moved on to Phase 3. The first agent is amadacycline (Figure
1.28). This drug is a tetracycline derivate, and is being investigated for the treatment of
cSSTI, diabetic foot infections, and community-acquired pneumonia. The second agent
that has completed Phase 2 trials is delafloxacin (Figure 1.29). It is a quinolone
derivative that is being investigated for the treatment of cSSTI and community-acquired
pneumonia. The final agent that has completed Phase 2 clinical trials is V710. This
agent is a Staphylococcus aureus vaccine, which represents another novel mechanism of
action in the treatment of gram-positive bacteria infections. It is being considered for a
single dose treatment for patients scheduled for cardiothoracic surgery and kidney disease
patients.
Phase 2 Ongoing

There are a number of agents in the antibacterial pipeline that are currently in
Phase 2 clinical trials. The first agent is nemonoxacin. It is a non-fluorinated quinolone
that is being investigated for the treatment of community- and hospital-acquired
pneumonia and diabetic foot infections. The next agent, TD-1792, is a unique hybrid
antibiotic. It combines the potency and efficacy of vancomycin and a cephalosporin in
one antibacterial agent. It is targeted toward the treatment of cSSTI and bacteraemia.
Radezolid (Figure 1.30) is the next agent currently undergoing Phase 2 clinical trials. It
is a member of the oxazolidinone class of antibiotics. It is being tested for the treatment
of mild-to-moderate community-acquired pneumonia and uncomplicated skin and soft
tissue infections. PZ-601 is another agent in the pipeline undergoing Phase 2 trials. It is
a carbapenem antibiotic that is being investigated for the treatment of cSSTI.
The next agent undergoing Phase 2 trials is NXL 103. This drug belongs to the
streptogramin class of antibiotics. It is a combination of the agents linopristin and
floprisitin. It is being investigated for the treatment of community-acquired pneumonia.
Another agent currently undergoing Phase 2 trials is torezolid (Figure 1.31). Torezolid is
an oxazolidinone antibiotic that is being investigated for the treatment of cSSTI and
hospital-acquired pneumonia. WCK-771 is in Phase 2 clinical trials for the treatment of
gram-positive infections. It is a quinolone antibiotic. More specifically, it is the active
isomer of nadifloxacin. Finally, zabofloxacin is a quinolone antibiotic in Phase 2 trials
for the treatment of community-acquired respiratory infections.
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Torezolid
Figure 1.31: Structure of Torezolid
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Phase 1 Completed

There are two agents that have completed Phase 1 clinical trials, but have yet to
advance on to Phase 2. The first agent is CEM-101. This agent is an oral macrolide
antibiotic that is being investigated for the treatment of community-acquired pneumonia.
The second agent that has completed Phase 1 clinical trials is BC-3205. This agent
belongs to the pleuromutilin class of antibiotics, but unlike the current pleuromutilins
which are topical agents, BC-3205 is an oral antibiotic. It is being investigated for the
treatment of cSSTI and community-acquired pneumonia.
Phase 1 Ongoing

The agents in the section are currently involved in Phase 1 clinical trials. The first
agent is RWJ-416457 (Figure 1.32). This agent belongs to the oxazolidinone class of
antibiotics and is being investigated for the treatment of gram-positive infections. The
next drug is PMX-30063. This is a very unique and novel agent. It is classified as a
small molecule mimetic of a host defense protein, defensin. It is the first known small
molecule mimetic of a host defense protein to enter human clinical trials for systemic use.
This agent represents an entirely new class of antibiotic drugs. It is being investigated for
the treatment of staphylococcal infections. The last two agents that are currently in Phase
1 clinical trials both represent a novel class of antibiotics, fatty acid biosynthesis (Fab)
inhibitors.52 The first agent is AFN-1252 (Figure 1.33), and it is a FabI inhibitor. The
second agent is platensimycin (Figure 1.34), and it is a FabF inhibitor. Both of these
agents are being investigated for the treatment of staphylococcal infections.
Antibiotics in the Pipeline: Gram-Negative
Over the past several years, there has been a drastic increase in the number of
multi-drug resistant isolates of gram-negative bacteria.53 The outlook for antibiotics that
treat gram-negative infections is not as positive as in the gram-positive arena. This is
causing major concern within the scientific community. There are currently no
antibiotics being review for final approval by the FDA. There are not even any agents
currently in Phase 3 clinical trials. This is a major issue because without any agents that
have advanced past Phase 2 clinical trials, it will be at least 5 years before the first agent
becomes routinely available in the clinic. While most of the agents in the pipeline are
modifications of existing classes of antibiotics, there are a few novel classes rising
through the pipeline as well. Given the widespread resistance problem and the propensity
to intensify the effect of class-specific resistance, most scientists would prefer to have
more novel classes with no pre-existing potential cross-resistance.54
Phase 2 Ongoing

There are currently three agents that are in Phase 2 clinical trials for the treatment
of gram-negative bacteria. The first agent is combination agent. It combines ceftazidime
and NXL 104 (Figure 1.35). Ceftazidime is a cephalosporin, and NXL 104 is a new
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β-lactamase inhibitor. These agents are used in combination so as to increase the
cephalosporin’s activity against most β-lactamase producing bacteria. This would be the
first resumption of this established approach to protect a β-lactam antibiotic against
resistance caused by β-lactamases since the approval of piperacillin/tazobactam in 1993.
This combination has been shown to be stable against class A and class C β-lactamase,
and is being tested for the treatment of complicated urinary tract infections.
The second agent in Phase 2 clinical trials is IC43. This is a recombinant subunit
vaccine consisting of two outer membrane proteins of Pseudomonas aeruginosa. It is
being tested for the treatment of ventilator-associated pneumonia. The final agent that is
currently undergoing Phase 2 trials is KBPA101. This agent is a monoclonal antibody
that targets Pseudomonas aeruginosa serotype O11. It is also associated with the codevelopment of a multivalent diagnostic test for rapid serotyping.
Phase 1 Ongoing

The first agent that is currently undergoing Phase 1 clinical trials is KB001. This
is a humaneered monoclonal antibody fragment. It is an antivirulence antibody that
targets PcrV protein of the Type III secretion system of Pseudomonas aeruginosa. It is
being tested for the treatment of cystic fibrosis and ventilator-associated pneumonia. The
next agent is ACHN-490 (Figure 1.36). It is an aminoglycoside that is active against
aminoglycoside-resistant gram-negative pathogens. The final agent is CB-182804. It is a
lipopetide that shows activity against Escherichia coli, Acinetobacter, Pseudomonas
aeruginosa, and Klebsiella.
Pre-clinical

There are a number of agents that are either currently in pre-clinical trials or have
completed pre-clinical trials, but are not in Phase 1 trials. The first agent that has
completed the pre-clinical trials is ceftaroline with NXL 104. This is another
cephalosporin combined with a new β-lactamase inhibitor. This agent proves to be stable
against class A and class C β-lactamases. It is also shows efficacy against enterobacteria,
Pseudomonas aeruginosa, and MRSA. The last agent that has completed clinical trials is
POL7080. POL7080 belongs to a novel class of antibiotics called protein epitope
mimetics. This agent is specific for Pseudomonas aeruginosa.
The following agents are all currently involved in pre-clinical trials. The first is
CXA-101 (Figure 1.37). This agent is a cephalosporin and is more stable against class C
β-lactamases than ceftazidime. The next agent is BAL 30072 (Figure 1.38). It is a
monobactam antibiotic. It is stable against class C and class B enzymes (metallo-βlactamases).
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Concluding Introductory Remarks

The entire drug discovery process is mediated by the role that medicinal chemists
play. Without the knowledge and guidance of medicinal chemists, the agents discussed
in this chapter would, for the most part, not exist. Medicinal chemistry plays a pivotal in
the process for drug development. Medicinal chemists can begin the discovery process
by finding a hit compound. The hit compound can be identified in a number of ways;
including computationally, through high-throughput screening, or chemical intuition
developed over numerous years of training and study. From the hit compound, medicinal
chemists can then lead that compound through the optimization process. During the
optimization process, synthetic medicinal chemists utilize their training and knowledge to
improve the potency, efficacy, and pharmaceutical profile of the hit compound into a lead
compound. This lead compound can then begin evaluation for pre-clinical trials in hopes
that it will enter clinical trials to become a marketable drug.
It is clear from the information presented in this chapter that the need to develop
novel antibiotics is still strong. There has been a push to develop new agents for the
treatment of gram-positive bacteria, due to the prevalence of MRSA, and that is now
reflected in the antibiotic pipeline. There are several agents in advanced the advanced
stages of approval for gram-positive infections. However, the real dilemma is present in
the realm of gram-negative infections. There is an ever increasing prevalence of gramnegative bacterial resistance; this could be related to the push to develop new grampositive active agents while gram-negative infections were all but ignored. As of late,
there has been a push to develop new gram-negative active agents. These agents are just
beginning to filter into the antibacterial pipeline, and therefore have a long ways to go
before they are available for human use. The time that is going to elapse between now
and when these agents become available is going to be pivotal to see how bad the issue of
gram-negative resistance becomes. The current antibacterial pipeline does show some
promise for the future of antibacterial research, but it must people should not become lax.
This field is always in need of novel research, and should not be neglected.
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CHAPTER 2: NOVEL UREA DERIVATIVES AS ANTI-TUBERCULOSIS
AGENTS
Introduction to Tuberculosis
Mycobacterium tuberculosis is the causative agent of human tuberculosis (TB).
This bacteria was first described in detail by Robert Koch in 1882.55,56 TB primarily
manifests itself as a respiratory tract infection attacking the lungs, but it can also affect
the central nervous system, lymphatic system, circulatory system, bones, joints, and even
the skin.57 The respiratory manifestation of the disease can be easily spread via aerosol
droplets that result from coughing, sneezing, speaking, or other forms of expulsion from
the mouth and nose.58 TB is a deadly disease. It is estimated that one-third of the
world’s population (two billion people) is infected with the TB bacilli. Of the two billion
people infected with the bacilli, approximately eight million will develop active
tuberculosis and approximately 1.6 million people will die per annum.58-63

There are two stages of this disease: latent TB and active TB.64,65 In general,
patients with the latent form of the disease are asymptomatic and not contagious. The
opposite is true for patients with the active TB. Only about 5-10% of individuals with the
latent form of TB will ever develop active TB. However, that statistic changes
dramatically if the patient becomes immunocompromised, such as with human
immunodeficiency virus (HIV). In such an instance, the rate increase to 10% per year.66
While TB is a very deadly disease, treatment options are available.
Treating Tuberculosis
Chemotherapy for TB started in the 1940s. In 1943, anti-TB research resulted in
the discovery of active anti-TB agents, and strategies have been subsequently devised to
treat TB.58,67-70 Chemotherapeutic action is required once a patient develops active TB.
There are two lines of agents used in the treatment of TB depending upon whether or not
the bacteria have developed resistance to the first set of agents. The first-line therapy for
TB consists of rifampin (RIF), isoniazid (INH), pyrazinamide (PZA), streptomycin (SM),
and ethambutol (EMB) (Figure 2.1). The second-line agents, which are reserved for
cases of resistance, retreatment, or intolerance to first-line drugs, include ethionamide,
para-aminosalicyclic acid, cycloserine, capreomycin, and kanamycin (Figure 2.2).5 Due
to the fact that TB has the ability to manifest itself in a latent state, and it is also a slow
growing bacteria, the treatment time for a regimen of antibiotics is usually between 6-9
months to effectively rid the body of the bacteria.57 With the current antibiotics,
regimens shorter than six months are not allowed due to the high rate of relapse.71 The
reason the second-line agents are not used as first-line is due to the fact that although they
are active against TB, they are usually not well tolerated having higher incidences of
adverse side effects, and are less efficacious requiring even longer therapy to rid the body
of the bacteria.5
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Isoniazid

The antibiotic isoniazid (INH) is an orally active synthetic agent that was
discovered in the mid 1900s to be active against tuberculosis. However, INH is only
active against the actively growing form of the bacteria.57 INH exerts its antituberculosis activity by binding to one of the condensing enzymes (inhA) in the fatty acid
biosynthesis pathway.72-75 A mutation within this gene was shown to confer resistance to
INH, thus suggesting that inhA is the target of this drug.76,77 It is a prodrug that must be
enzymatically activated in the body. In the case of INH, it is activated by the TB
catalase-peroxidase enzyme (katG) to the activated radical acyl anion.78,79 This form of
the drug reacts with nicotinamide adenine dinucleotide (NADH) to form a complex that
binds tightly to inhA inhibiting the synthesis of mycolic acids in the mycobacterial cell
wall.72 It has been reported that NAD-adducts have a secondary effect on almost every
aspect of mycobacterial metabolism.80
Rifampin

Rifampin is an orally active, highly effective semi-synthetic antibiotic. It shows
bactericidal activity against all populations of mycobacteria. The introduction of
rifampin to the standard treatment regimen reduced the duration of chemotherapy by half,
from 18 to 9 months.57 RIF inhibits the β-subunit of RNA polymerase, thus preventing
the transcription of DNA to RNA and the successive translation of proteins in
mycobacteria.81 Resistance to RIF develops when a mutation occurs in the gene
responsible for the β-subunit of the RNA polymerase (rpoB) causing the antibiotic to no
longer be able to bind RNA polymerase.82
Pyrazinamide

Pyraziamide (PZA) is an orally active synthetic analog of nicotinamide. It
exhibits slightly bactericidal activity on actively replicating bacteria, but overall is
thought to act by a sterilizing effect.58 The activity of PZA is pH dependent. Good in
vivo activity is seen at pH 5.5, but it is nearly inactive at neutral pH.5 PZA is also a
prodrug that must be enzymatically activated by pyrazinamidases to convert it to its
active from, pyrazinoic acid, which inhibits energy metabolism.83-85 The introduction of
PZA into the treatment regimen reduced treatment time from 9 months to 6.5,86,87
Ethambutol

Ethambutol (EMB) is synthetic amino alcohol.88-90 Ethambutol is a bacteriostatic
agent that inhibits arabinogalactan biosynthesis, a primary component of the
mycobacterial cell wall.91,92 It disrupts the cell wall of the mycobacteria allowing for
other agents to better penetrate the bacilli and destroy it more effectively. EMB
resistnace involves a gene over expression and mutations of arabinosyl transferase which
is encoded by the embB gene.92,93
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Streptomycin

Streptomycin is an aminoglycoside antibiotic.58 It is bacteriostatic, and used in
the treatment of drug resistant tuberculosis.57 Streptomycin acts by penetrating the inner
membrane of Mycobacterium tuberculosis and binding to the 30S ribosomal subunit, thus
inhibiting protein synthesis.94 This agent is associated with many toxic manifestations on
the peripheral and central nervous system at higher doses, and hypersensitivity reactions,
therefore it is not a drug of popular choice.58
Need for Novel Anti-Tuberculosis Agents
A number of once active anti-tuberculosis drugs are now inactive due to the ever
increasing rise in drug resistant strains of tuberculosis.58 This is a frightening statistic in
itself, but coupled with the fact that there have been no new first-line chemotherapeutic
agents developed to combat TB in the last 35 years, it becomes staggering.9 While these
agents may still be effective, there are still problems in treating TB, including poor
patient compliance which leads to the development of more drug resistant strains. There
is a lack in patient compliance due in large part to the fact that the current treatment
regimen lasts 6-9 months. The length of the treatment is due to the difficulty in killing
off the latent and slow-growing bacteria. Drug-resistant TB is a major public health issue
in many developing countries around the world.59
The appearance of multi-drug resistant TB (MDR-TB) occurs when drugsusceptible TB is improperly or incompletely treated. According to the World Health
Organization (WHO), MDR-TB is defined as a resistance to the two most effective firstline TB agents: rifampin and isoniazid.59 When a strain of TB becomes unresponsive to
any fluoroquinolone and at least one of the three second-line agents (capreomycin,
kanamycin, and amikacin), it becomes described at extensively drug-resistant TB (XDRTB).59 There are several ways in which a person can become infected with drug-resistant
TB, including not taking the prescribed course of drugs appropriately or becoming
infected by an individual with a drug-resistant strain.65 As is evident by these facts, there
is an ever growing need to develop novel agents for the treatment of tuberculosis. These
new agents need to be potent, fast-acting, have an excellent
pharmacokinetic/pharmacodynamic (PK/PD) profile, have a high therapeutic index, and
preferably have a novel mechanism of action as to avoid cross-resistance with other
agents.
Targeting Epoxide Hydrolase

Increasing drug resistance and poor activity of existing therapies towards the
latent stage of Mycobacterium tuberculosis infection has produced a clear need to
develop novel therapeutics to treat tuberculosis.95 Thus fast-acting drugs with novel
mechanisms of action that are not cross resistant to existing drugs are being sought
actively. To tackle this problem two primary screening strategies are being applied in
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tuberculosis drug discovery-target based high throughput screening and phenotypic
minimum inhibitory concentration (MIC) based screening of whole cell bacteria.
Although target / enzyme based high throughput screening for new tuberculosis
therapeutics has been widely adopted, this strategy has not produced many notable
successes. This experience mirrors the success of other antibacterial drug discovery
programs.96 On the contrary, phenotypic direct MIC based screening of commercial and
proprietary libraries has recently produced a number of interesting clinical candidates
including the diaryl quinolone, TMC207, and benzothiazinone, BTZ043,97,98 for which
the ultimate enzymatic target and antitubercular mode of action for these compounds was
derived after potent inhibitors were identified.
We have adopted an analogous phenotypic screening approach to screen various
available chemical libraries directly for anti-tuberculosis activity and then follow up hits
that are shown to be selective with mode of action studies to produce novel validated
anti-tubercular drug candidates.99 This study included the screening of a compound
library from LeadScreen (Tripos) for anti-tuberculosis activity by microbroth dilution in
Middlebrook 7H9 media. This screen identified urea derivative 1, which displayed an
MIC of 0.3 µM (0.01 µg/ml) (Figure 2.3). Interestingly, the structure of the urea
compound 1 is very similar to inhibitors of mammalian soluble epoxide hydrolase
(sEH)100 (Figure 2.4) and the recently reported inhibitors of the tuberculosis epoxide
hydrolase (EH) enzyme B.101
Initially it was thought that the tuberculosis genome contained six putative EH
enzymes, but it is now suggested that the M. tuberculosis genome contains at least 30
members of the EH family.101 Consequently, these enzymes may represent good targets
for tuberculosis drug discovery as they play essential roles in the detoxification of various
substances in addition to lipid metabolism. Since M. tuberculosis contains several EHs,
which are likely to be redundant, a target driven approach appears inferior to the
phenotypic MIC for rapidly determining the initial therapeutic potential of EH inhibition.
Currently, there are no reports on the whole cell anti-tubercular activity of EH inhibitors.
In this study, the three sections of hit 1 were systematically modified to develop a detail
anti-tubercular structure activity relationship for this series of compounds that represent
analogs of EH inhibitors.
Chemistry

The optimization of compound 1 began by modifying each side of the urea moiety
with a selection of substituents to probe the anti-tubercular structure activity relationship.
These positions are shown as R (aryl) and R΄ (adamantyl). The synthesis of these
derivatives was carried out by reacting the desired amine and with an isocyanate in
dichloromethane in the presence of triethylamine (Scheme 2.1). Using this facile
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chemistry, an array of compounds (1-30) was rapidly synthesized using parallel synthesis
all in good yields (>75%).
The second series of compounds was synthesized focusing on modifications of
the urea moiety (Scheme 2.2A). The first compound targeted was the thiourea derivative
31 as there are already known thiourea drugs such as isoxyl and thiocarlide.102,103 As
shown in Scheme 2.2A, this synthesis was identical to the urea synthesis with the
exception that the isothiocyanate was used in place of the isocyanate to give 31 in good
yield.
The synthesis of the carbamate derivative 32 is discussed next. This synthesis
coupled the adamantyl alcohol with the phenyl isocyanate in order to form the desired
product again in high yield (Scheme 2.2B). Further modification of the urea moiety is
shown by the synthesis of the mono- and dimethylated derivatives 33 and 34 (Scheme
2.2C). The synthesis of the 33 started from 1, which was selectively deprotonated at the
more acidic urea nitrogen adjacent to the phenyl ring with n-butyl lithium at low
temperature. The anion was then reacted with iodomethane to form compound 33 in
good yield. Di-N-methylated urea 34 was obtained in an analogous fashion using
increased equivalents of n-butyl lithium and iodomethane.
The final series of compounds synthesized aimed to decrease the lipophilicity by
the introduction of oxygen containing substituents, as poor solubility was noted in
preliminary testing of the first two series of compounds. The first compound targeted
was reference compound 36, a known inhibitor of human EH’s which has been shown to
be orally bioavailable. 36 was synthesized according to the published synthesis of T.
Kasagami et. al. (Scheme 2.3).104,105
Other oxygenated urea analogs 37-41 were synthesized according to Scheme 2.1.
To complete the series compound 42, the urea derivate of the tuberculosis drug isoxyl,
was synthesized (Scheme 2.4). 42 was synthesized by alkylating 4-nitrophenol with 1bromo-4-methylpentane to produce the O-alkylated intermediate. This nitro intermediate
was then reduced by hydrogenolysis to produce the aniline intermediate. This compound
was then reacted with triphosgene or thiophosgene to produce the 42 and 43 (Isoxyl) in
acceptable yields.
Results and Discussion

Overall, the first series of urea compounds showed good activity primarily against
M. tuberculosis (H37Rv) (Table 2.1). In this series, compounds 1, 3, 11, 20, 24 showed
the best activity with an MIC value of 0.01 µg/mL that is comparable to the antituberculosis drug isoniazid (0.01 µg/mL). Some significant structure activity
relationships (SAR) has emerged from this data. The one substituent has a strong
preference for the bulky aliphatic ring system such as adamantly. Substituting adamantyl
for a cyclohexyl 8 or cyclopentyl 9 considerably decreased the activity, while a
cyclooctyl 7 ring system only minimally decreased the activity to a level comparable to
41

Scheme 2.2: Synthesis of Variations around Urea Moiety

Reagents and Conditions: (a) triethylamine, dry dichloromethane, room temperature,
overnight; (b) triethylamine, dry dichloromethane, room temperature, overnight; (c) (i) nBuLi, dry THF, -78˚C; (ii) iodomethane, reflux, 24 hr; (d) (i) n-BuLi, dry THF, -78˚C;
(ii) iodomethane, reflux, 24 hr.

Scheme 2.3: Synthesis of Compound 36
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Reagents and Conditions: (a) conc. H2SO4, dry MeOH, reflux, 12 hr; (b) dry
dichloroethane, reflux, 4 d.
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Scheme 2.4: Synthesis of Compounds 42 and 43
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Reagents and Conditions: (a) 1-bromo-4-methylpentane, NaOH, DMF, 65˚C, overnight;
(b) Pd/C, H2, ethanol, overnight; (c) triphosgene, triethylamine, DCM, room temperature,
overnight; (d) thiophosgene, triethylamine, DCM, room temperature, overnight.
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Table 2.1:

In Vitro Antibacterial Activity of First Urea Series
MIC
(µg/mL)

Cytotox
(µg/mL)

1

0.01

219

2

0.4

725.8

3

0.01

1.18

4

6

129.7

5

0.02

16

6

0.2

15.5

7

0.8

63.4

8

12.5

15.9

9

50

nda

10

0.4

7.1

11

0.01

30.2

No.

Structure

R

R

44

Table 2.1:
No.

Continued
MIC
(µg/mL)

Structure

Cytotox
(µg/mL)

12

0.1

9.7

13

3.125

4.2

14

1.6

26.4

15

50

23.4

16

12.5

371.9

17

12.5

170.9

18

10

25

19

0.39

11.62

20

0.01

174.8

21

0.2

20

22

0.02

4.34

23

3.3

186.4

24

0.01

>1000

25

6

342.3

O
R
N
H

Cl

N
H

R

45

Table 2.1:

Continued
MIC
(µg/mL)

Cytotox
(µg/mL)

6

>1000

27

3

nd

28

0.8

25.3

29

1.6

38.5

30

1.6

193.2

No.

Structure
O
R
N
H

Cl

N
H

R

26

R

a

nd = not determined
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the drug ethambutol (0.8 µg/mL). Substitution in the aryl ring at the meta and/or para
positions (Compounds 10-14) were more tolerated with those substitutions not having a
major impact on the anti-tuberculosis activity. In the group of compounds which contain
the trifluorophenyl moiety (Compounds 1-9), the adamantyl compounds 1 and 3 exhibit
the best activity with potent MIC values of 0.01 µg/mL.
It can be seen that within this series the bulky hydrophobic adamantyl group is
preferred over a straight-chain alky group 4 or even a simple cyclic alkyl group 8 and 9
which lack the bulk of the adamantyl group. With regard to compounds that only contain
aliphatic groups (Compounds 15-21), it can be seen that the best MIC value is displayed
by the most hydrophobic compound with the longest alkyl chain 20. When comparing
the compounds with the 3-chloro-4-methylphenyl substitution (Compounds 22-26), it can
be seen that compound with a bulky alkyl rings on the opposite side (adamantyl and
cyclooctyl) produce the most active compounds (22 and 24). This trend continues in the
compounds in the 2-fluoro-3-(trifluoromethyl)phenyl arylurea series 27-30.
The MIC data for the second series of compounds in which the central urea
moiety was modified is shown below (Table 2.2). In this series, it is clearly seen that the
unmodified urea moiety is preferred for best anti-tuberculosis activity. Introduction of a
thiourea 31 produces a decrease in activity. Replacing the urea with a carbamate 32
produces a 10-fold larger decrease in potency. Mono N-methylation of the urea 33 shows
similar decrease in activity and di-N-methlyation 34 produces an even greater decrease in
activity.
The MIC data for the third series of oxygenated ureas is shown below (Table 2.3).
Compounds 35 and 36 showed good antitubercular activity while the remaining
compounds 37-41 had much poorer activity. It is of interest to note that 35 and 36 were
the only two in this series which contained the preferred SAR arrangement of having a
bulky aliphatic ring on one side of the molecule and having an aromatic ring on the other.
When comparing compounds 37 and 38 to aliphatic analog 28, it can be seen that placing
the oxygen in the alkyl chain dramatically decreases antitubercular activity. Compound
42, the urea analog of thiourea tuberculosis drug thiocarlide, was found to be inactive.
This is in contrast to the comparison of compounds 1 and 31, where it was shown that
replacing the urea moiety with a thiourea decreased the activity but 31 still had some
antitubercular activity demonstrating the contribution of the adamantyl and phenyl groups
to the overall activity. It can mean that thiocarlde acts on a different target than the
compounds selected here.
Conclusions

In this study, clear structure activity relationships (SAR) for anti-tubercular
activity of urea-based EH inhibitors has emerged with the best compounds containing a
1-cylcoalkyl-3-phenyl disubstituted urea structure. The 1-3 disubstituted urea moiety was
shown to be most active over other urea substitution patterns and urea bioisosteres. For
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Table 2.2:
Moieties

In Vitro Antibacterial Activity of Compounds with Varying Urea

M. tb
MIC (µg/mL)

No.
1
31
32
33
34

X

Y

Z

NH
NH
O
NH
NMe

O
S
O
O
O

NH
NH
NH
NMe
NMe

0.01
0.8
6
6
12
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Table 2.3: In Vitro Antibacterial Activity of Miscellaneous Urea Compounds

No.

MIC Cytotox
(µg/mL) (µg/mL)

Structure

0.4

13.4

36

0.39

30.3

37

50

nda

38

100

20.4

39

25

6.4

25

264.8

>100

nd

200

nd

2.5

nd

35

R

40

O
O
N

41

F

O
N
H

F
F

O

42
H
N

Thiocarlide
O
a

H
N
S

O

nd = not determined
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the cycloalkyl ring subsituent, a strong preference for bulkyl groups such as adamantyl
was preferred for anti-tubercular activity.
This is consistent with previous findings by Biswal et al.,101 which indicates the
importance of the adamantyl substituent in inhibiting M. tuberculosis EH enzyme B.
Therefore, bulky groups such as adamantyl appear relevant for both enzyme and whole
cell activities. This is noteworthy as other adamantyl analogs have been shown to have
good anti-tubercular activity; most notably the clinical candidate adamantyl diamine
SQ109 and admanatyl amides discovered through high throughput screening by the
National Institutes of Health (NIH) sponsored Tuberculosis Antimicrobial Acquisition
and Coordinating Facility (TAACF) program.91,106,107 Substitutions to the phenyl ring
were well tolerated; suggesting further analogs of this position may be worthwhile.
This SAR provides support that α/β-hydrolase fold EHs may be actual targets of
ureas in M. tb due to structural similarities of these compounds to human sEH inhibitors.
Evidence for a specific mode of action is bolstered by a lack of correlation between
lipophilicity and MIC against M. tb, suggesting that activity was not due to membrane
disruption. This is further supported by several compounds exhibiting good activity
against M. smegmatis and the general lack of activity of most analogs against other grampositive and –negative bacterial pathogens including Staphylococcus aureus, Bacillus
anthracis, Esherichia coli, Pseudomonas aeruginosa and Klebsiella pneumoniae. Both
of these affects will be more closely analyzed in upcoming studies. In general all ureabased compounds with potent MICs that were comparable to isoniazid and ethambutol
(0.01-1.6 µg/mL), showed good therapeutic selectivity for M. tuberculosis with
selectivity indices of 16.5->21,900. Importantly, this indicates that selective inhibitors
of the mycobacterial EHs may be obtained. Increasing solubility, metabolic stability and
selectivity away from inhibition of human EHs are currently the principal design drivers
that are being used to further optimize this series.
Currently, computer-based structure docking experiments are being conducted my
members of Dr. Richard Lee’s laboratory. These findings will be used to further guide
the future directions of this project. Initial studies are being performed in an effort to
establish a model which can effectively predict that activity of potential inhibitors before
they are synthesized in the laboratory. This computer model provides details of how the
inhibitors bind into the active site of the epoxide hydrolase enzyme found in
Mycobacterium tuberculosis (Figure 2.5). This figure depicts the modeled interactions of
compound 1 (ball and stick form with yellow carbons) within the active site of
Mycobacterium tuberculosis epoxide hydrolase B (EphB) with the catalytic residues
(tube form with grey carbons). Panel A shows the 90o left side view of the hydrophobic
pocket where the adamantyl functionality resides. Panel B shows the front view of the
hydrogen bonding network with the catalytic residues Tyrosine 164, Tyrosine 272, and
Aspartic Acid 104 to the urea moiety of compound 1. Panel C displays the 90o right side
view and key interactions of the aromatic binding pocket.
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Figure 2.5:

Hydrogen Bonding Network
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Experimental Section

Chemistry
All anhydrous solvents and starting materials were purchased from Aldrich
Chemical Co. (Milwaukee, WI). All reagent grade solvents used from chromatography
were purchased from Fisher Scientific (Suwanee, GA) and flash column chromatography
silica cartridges were obtained from Biotage Inc. (Lake Forest, VA). The reactions were
monitored by thin-layer chromatography (TLC) on pre-coated Merch 60 F254 silica gel
plates and visualized using ultraviolet (UV) light (254 nm). A Biotage FLASH column
chromatography system was used to purify mixtures. All 1H nuclear magnetic resonance
(NMR) spectra were recorded on a Varian INOVA-500 spectrometer. Chemical shifts (δ)
are reported in parts per million relative to the residual solvent peak or internal standard
(tetramethylsilane), and coupling constants (J) are reported in hertz (Hz). Mass spectra
were recorded on a Bruker Esquire liquid-chromatography mass-spectrometer using
electrospray ionization. Purity of the products was confirmed before testing by analytical
reverse phase-high performace liquid chromatography on a Shimadzu high-performance
liquid-chromatography system, and all final compounds had a purity of 95% or greater as
determined by RP-HPLC. Gradient Conditions: solvent A (0.1% Trifluoroacetic Acid
(TFA) in water) and solvent B (acetonitrile): 0-2.00 min 100& A, 2.00-7.00 min 0-100%
B (linear gradient), 7.00-8.00 min 100% B, UV detection at 254 nm. Melting points were
obtained on the OptiMelt MPA100 Automated Melting Point System.
General Method for the Synthesis of Urea Compounds
In a round bottom flask equipped with a stir bar, 1.2 mmol of the appropriate
amine was added to 10 mL of anhydrous dichloromethane. To this solution, 1.0 mmol of
the appropriate isocyanate followed by 3.6 mmol of triethylamine was added. The
reaction was stirred at room temperature overnight. The solvent was removed by rotary
evaporation. The resulting residue was purified by flash chromatography using a
petroleum ether to ethyl acetate gradient to elute the final compound.
1-(2-adamantyl)-3-(2,3,4-trifluorophenyl)urea (1). 1H NMR (DMSO-d6): δ 1.58 (2H,
d, J = 12 Hz), 1.80 (12H, m), 3.78 (1H, d, J = 8.0 Hz), 6.96 (1H, d, J = 8.0 Hz), 7.20 (1H,
q), 7.96 (1H, m), 8.51 (1H, s). RP-HPLC: tR = 7.18 min. ESI-MS m/z: 347.1 [M + Na]+.
Mp: 229-230 °C.
1-(1-adamantyl)-3-(2,3,4-trifluorophenyl)urea (2). 1H NMR (DMSO-d6): δ 1.63 (6H,
s), 1.93 (6H, s), 2.03 (3H, s), 6.44 (1H, s), 7.16 (1H, q, J = 10.0 Hz), 7.88 (1H, m), 8.26
(1H, s). RP-HPLC: tR = 7.29 min. ESI-MS m/z: 347.1 [M + Na]+. Mp: 216-219 °C.
1-(1-(1-adamantyl)methyl)-3-(2,3,4-trifluorophenyl)urea (3). 1H NMR (DMSO-d6): δ
1.55 (12H, m), 1.94 (3H, m), 2.81 (2H, d, J = 6.0 Hz), 6.60 (1H, t, J = 5.5 Hz), 7.19 (1H,
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q, J = 9.5 Hz), 7.92 (1H, m), 8.44 (1H, s). RP-HPLC: tR = 7.08 min. ESI-MS m/z: 361.3
[M + Na]+. Mp: 171-173 °C.
1-heptyl-3-(2,3,4-trifluorophenyl)urea (4). 1H NMR (DMSO-d6): δ 0.87 (3H, t, J = 6.5
Hz), 1.24 (8H, s), 1.42 (2H, m), 3.08 (2H, q, J = 6.5 Hz), 6.57 (1H, t, J = 5.0 Hz), 7.19
(1H, q, J = 9.0 Hz), 7.84 (1H, m), 8.40 (1H, s). RP-HPLC: tR = 7.04 min. ESI-MS m/z:
311.1 [M + Na]+. Mp: 96-98 °C.
1-(2,3,4-trifluorophenyl)-3-(2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl)urea (5). 1H
NMR (DMSO-d6): δ 0.90 (1H, d, J = 9.5 Hz), 1.00 (3H, s), 1.06 (3H, d, J = 7.0 Hz), 1.20
(3H, s), 1.52 (1H, m), 1.79 (2H, m), 1.91 (1H, m), 2.44 (2H, m), 3.97 (1H, quintuplet, J =
8.0 Hz), 6.70 (1H, d, J = 8.0 Hz), 7.18 (1H, q, J = 9.5 Hz), 7.88 (1H, m), 8.26 (1H, s).
RP-HPLC: tR = 7.26 min. ESI-MS m/z: 349.1 [M + Na]+. Mp: 156-159 °C.
1-((6,6-dimethylbicyclo[3.1.1]heptan-2-yl)methyl)-3-(2,3,4-trifluorophenyl)urea (6).
1
H NMR (DMSO-d6): δ 0.86 (1H, d, J = 9.5 Hz), 1.00 (3H, s), 1.17 (3H, s), 1.44 (1H, m),
1.86 (5H, m), 2.10 (1H, m), 2.33 (1H, m), 3.08 (2H, m), 6.62 (1H, t, J = 5.5 Hz), 7.17
(1H, q, J = 10.0 Hz), 7.86 (1H, m), 8.38 (1H, s). RP-HPLC: tR = 7.30 min. ESI-MS m/z:
349.1 [M + Na]+. Mp: 105-107 °C.
1-cyclooctyl-3-(2,3,4-trifluorophenyl)urea (7). 1H NMR (DMSO-d6): δ 1.55 (13H, m),
1.76 (2H, t, J = 9.5 Hz), 6.63 (1H, d, J = 8.0 Hz), 7.18 (1H, q, J = 9.5 Hz), 7.89 (1H, m),
8.31 (1H, s). RP-HPLC: tR = 6.98 min. ESI-MS m/z: 323.1 [M + Na]+. Mp: 160-163 °C.
1-cyclohexyl-3-(2,3,4-trifluorophenyl)urea (8). 1H NMR (DMSO-d6): δ 1.19 (3H, m),
1.32 (2H, m), 1.53 (1H, m), 1.65 (2H, m), 1.80 (2H, m), 3.48 (3H, m), 6.60 (1H, d, J =
9.0 Hz), 7.20 (1H, q, J = 10 Hz), 7.90 (1H, m), 8.33 (1H, s). RP-HPLC: tR = 6.39 min.
ESI-MS m/z: 295.0 [M + Na]+. Mp: 188-191 °C.
1-cyclopentyl-3-(2,3,4-trifluorophenyl)urea (9). 1H NMR (DMSO-d6): δ 1.37 (2H, m),
1.59 (4H, m), 1.84 (2H, m), 3.94 (1H, q, J = 6.5 Hz), 6.66 (1H, d, J = 7.5 Hz), 7.19 (1H,
q, J = 9.5 Hz), 7.90 (1H, m), 8.27 (1H, s). RP-HPLC: tR = 6.14 min. ESI-MS m/z: 281.0
[M + Na]+. Mp: 184-186 °C.
1-(2-adamantyl)-3-(4-cyanophenyl)urea (10). 1H NMR (DMSO-d6): δ 1.58 (2H, d, J =
12.0 Hz), 1.79 (12H, m), 3.78 (1H, d, J = 7.5 Hz), 6.67 (1H, d, J = 7.5 Hz), 7.55 (2H, d, J
= 8.5 Hz), 7.67 (2H, d, J = 8.5 Hz), 8.92 (1H, s). RP-HPLC: tR = 6.83 min. ESI-MS m/z:
296.1 [M + H]+. Mp: 217-219 °C.
1-(2-adamantyl)-3-phenethylurea (11). 1H NMR (DMSO-d6): δ 1.66 (14H, m), 2.68
(2H, t, J = 7.0 Hz), 3.24 (2H, q, J = 7.0 Hz), 3.67 (1 H, d, J = 8.0 Hz), 5.82 (1H, t, J = 5.5
Hz), 6.11 (1H, d, J = 8.5 Hz), 7.21 (3H, d, J = 6.0 Hz), 7.30 (2H, t, J = 7.5 Hz). RPHPLC: tR = 6.82 min. ESI-MS m/z: 299.2 [M + H]+. Mp: 115-117 °C.
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1-(3-acetylphenyl)-3-(2-adamantyl)urea (12). 1H NMR (DMSO-d6): δ 1.57 (2H, d, J =
12.0 Hz), 1.80 (13H, m), 2.55 (3H, s), 3.79 (1H, d, J = 7.5 Hz), 6.50 (1H, d, J = 7.5 Hz),
7.38 (1H, t, J = 8.0 Hz), 7.50 (1H, d, J = 8.0 Hz), 7.58 (1H, d, J = 8.0 Hz), 8.00 (1H, s).
RP-HPLC: tR = 6.63 min. ESI-MS m/z: 335.2 [M + Na]+. Mp: 213-215 °C.
1-(2-adamantyl)-3-benzylurea (13). 1H NMR (DMSO-d6): δ 1.52 (2H, d, J = 12.5 Hz),
1.78 (12H, m), 3.70 (1H, d, J = 8.0 Hz), 4.21 (2H, d, J = 6.0 Hz), 6.18 (1H, d, J = 8.0
Hz), 6.27 (1H, t, J = 6.0 Hz), 7.24 (3H, q, J = 7.5 Hz), 7.33 (2H, t, J = 7.5 Hz). RPHPLC: tR = 6.37 min. ESI-MS m/z: 285.2 [M + H]+. Mp: 205-207 °C.
1-(2-adamantyl)-3-(3-chloro-2-methylphenyl)urea (14). 1H NMR (DMSO-d6): δ 1.58
(2H, d, J = 12.5 Hz), 1.77 (10H, m), 1.91 (2H, d, J = 12.5 Hz), 2.26 (3H, s), 3.79 (1H, d,
J = 7.5 Hz), 6.91 (1H, d, J = 8.0 Hz), 7.03 (1H, d, J = 7.5 Hz), 7.10 (1H, t, J = 8.0 Hz),
7.87 (2H, m). RP-HPLC: tR = 6.98 min. ESI-MS m/z: 341.1 [M + Na]+. Mp: 254-257 °C.
1-(2-adamantyl)-3-isopropylurea (15). 1H NMR (DMSO-d6): δ 1.02 (6H, d, J = 6.5
Hz), 1.50 (2H, d, J = 12.5 Hz), 1.75 (12H, m), 3.64 (2H, m), 5.66 (1H, d, J = 7.5 Hz),
5.95 (1H, d, J = 8.0 Hz). ESI-MS m/z: 237.1 [M + H]+. Mp: 240-242 °C.
1-(2-adamantyl)-3-tert-butylurea (16). 1H NMR (DMSO-d6): δ 1.22 (9H, s), 1.50 (2H,
d, J = 12.0 Hz), 1.75 (12H, m), 3.64 (1H, d, J = 8.0 Hz), 5.70 (1H, s), 5.95 (1H, d, J = 8.5
Hz). ESI-MS m/z: 273.1 [M + Na]+. Mp: >300 °C.
1-(2-adamantyl)-3-propylurea (17). 1H NMR (DMSO-d6): δ 0.84 (3H, t, J = 7.0 Hz),
1.37 (2H, sextuplet, J = 7.5 Hz), 1.51 (2H, d, J = 12.5 Hz), 1.76 (12H, m), 2.94 (2H, q, J
= 7.0 Hz), 3.66 (1H, d, J = 8.0 Hz), 5.81 (1H, t, J = 5.5 Hz), 6.02 (1H, d, J = 8.0 Hz).
ESI-MS m/z: 237.1 [M + H]+. Mp: 194-196 °C.
1-(2-adamantyl)-3-cyclohexylurea (18). 1H NMR (DMSO-d6): δ 1.17 (5H, m), 1.51
(3H, d, J = 12.0 Hz), 1.72 (17H, m), 3.65 (1H, d, J = 7.5 Hz), 5.75 (1H, d, J = 8.0 Hz),
5.98 (1H, d, J = 8.5 Hz). ESI-MS m/z: 299.3 [M + Na]+. Mp: >300 °C.
1-(2-adamantyl)-3-pentylurea (19). 1H NMR (CDCl3): δ 0.93 (3H, t, J = 6.5 Hz), 1.35
(4H, m), 1.53 (2H, quintet, J = 7.5 Hz), 1.62 (2H, s), 1.76 (2H, s), 1.80 (1H, s), 1.86 (7H,
t, J = 11.0 Hz), 1.93 (2H, s), 3.19 (2H, q, J = 7.0 Hz), 3.81 (1H, s), 4.26 (1H, s), 4.64 (1H,
s). ESI-MS m/z: 287.1 [M + Na]+. Mp: 151-153 °C.
1-(2-adamantyl)-3-hexylurea (20). 1H NMR (DMSO-d6): δ 0.87 (3H, t, J = 6.5 Hz),
1.31 (8H, m), 1.50 (2H, d, J = 12.5 Hz), 1.76 (12H, m), 2.97 (2H, q, J = 6.5 Hz), 3.65
(1H, d, J = 8.0 Hz), 5.78 (1H, t, J = 5.5 Hz), 6.01 (1H, d, J = 8.5 Hz). ESI-MS m/z: 279.3
[M + H]+. Mp: 95-98 °C.
1-(2-adamantyl)-3-heptylurea (21). 1H NMR (CDCl3): δ 0.90 (3H, t, J = 6.0 Hz), 1.31
(8H, m), 1.52 (2H, t, J = 6.5 Hz), 1.66 (2H, m), 1.75 (2H, s), 1.77 (1H, s), 1.86 (7H, t, J =
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11.0 Hz), 1.93 (2H, s), 3.18 (2H, q, J = 6.5 Hz), 3.81 (1H, s), 4.34 (1H, s), 4.70 (1H, s).
ESI-MS m/z: 315.1 [M + Na]+. Mp: 83-86 °C.
1-(1-(1-adamantyl)methyl)-3-(3-chloro-4-methylphenyl)urea (22). 1H NMR (DMSOd6): δ 1.45 (5H, s), 1.64 (7H, m), 1.95 (3H, s), 2.23 (3H, s), 2.79 (2H, d, J = 6.0 Hz), 6.14
(1H, m), 7.06 (1H, m), 7.17 (1H, d, J = 8.0 Hz), 7.66 (1H, m), 8.46 (1H, s). RP-HPLC: tR
= 7.24 min. ESI-MS m/z: 355.3 [M + Na]+. Mp: 183-185 °C.
1-(3-chloro-4-methylphenyl)-3-heptylurea (23). 1H NMR (CD3OD): δ 0.93 (3H, m),
1.35 (8H, m), 1.54 (2H, m), 2.30 (3H, s), 3.19 (2H, t, J = 6.5 Hz), 7.13 (2H, m), 7.53 (1H,
s). RP-HPLC: tR = 6.99 min. ESI-MS m/z: 305.1 [M + Na]+. Mp: 99-101 °C.
1-(3-chloro-4-methylphenyl)-3-(3-fluorobenzyl)urea (24). 1H NMR (CD3OD): δ 2.30
(3H, s), 4.40 (2H, s), 7.00 (1H, t, J = 8.5 Hz), 7.08 (1H, d, J = 10.0 Hz), 7.15 (3H, m),
7.35 (1H, q, J = 6.5 Hz), 7.54 (1H, s). RP-HPLC: tR = 6.38 min. ESI-MS m/z: 315.1 [M +
Na]+. Mp: 146-148 °C.
1-(3-chloro-4-methylphenyl)-3-cyclooctylurea (25). 1H NMR (DMSO-d6): δ 1.63 (14H,
m), 2.23 (3H, s), 3.68 (1H, m), 6.13 (1H, d, J = 8.0 Hz), 7.05 (1H, d, J = 8.0 Hz), 7.16
(1H, d, J = 8.0 Hz), 7.65 (1H, s), 8.35 (1H, s). RP-HPLC: tR = 6.90 min. ESI-MS m/z:
317.2 [M + Na]+. Mp: 179-182 °C.
1-(3-chloro-4-methylphenyl)-3-(4-phenylbutan-2-yl)urea (26). 1H NMR (CD3OD): δ
1.20 (3H, d, J = 6.5 Hz), 1.77 (2H, q, J = 7.0 Hz), 2.29 (3H, s), 2.69 (2H, m), 3.82 (1H,
m), 7.19 (7H, m), 7.54 (1H, s). RP-HPLC: tR = 6.75 min. ESI-MS m/z: 339.1 [M + Na]+.
Mp: 111-113 °C.
1-(2-fluoro-3-(trifluoromethyl)phenyl)-3-heptylurea (27). 1H NMR (DMSO-d6): δ
0.86 (3H, t, J = 6.5 Hz), 1.27 (8H, m), 1.43 (2H, t, J = 6.5 Hz), 3.10 (2H, q, J = 6.5 Hz),
6.67 (1H, t, J = 5.5 Hz), 7.28 (2H, m), 8.42 (1H, t, J = 7.0 Hz), 8.55 (1H, s). RP-HPLC: tR
= 7.39 min. ESI-MS m/z: 343.1 [M + Na]+. Mp: 77-79 °C.
1-cyclooctyl-3-(2-fluoro-3-(trifluoromethyl)phenyl)urea (28). 1H NMR (CDCl3): δ
1.67 (14H, m), 1.90 (2H, m), 3.86 (1H, m), 7.25 (2H, d), 8.36 (1H, m). RP-HPLC: tR =
7.32 min. ESI-MS m/z: 355.1 [M + Na]+. Mp: 127-129 °C.
1-(2-fluoro-3-(trifluoromethyl)phenyl)-3-(4-phenylbutan-2-yl)urea (29). 1H NMR
(DMSO-d6): δ 1.13 (3H, d, J = 6.5 Hz), 1.71 (2H, d, J = 7.0 Hz), 2.62 (2H, d, J = 7.5 Hz),
3.70 (1H, m), 6.68 (1H, d, J = 7.0 Hz), 7.22 (7H, m), 8.47 (2H, m). RP-HPLC: tR = 7.12
min. ESI-MS m/z: 377.0 [M + Na]+. Mp: 145-148 °C.
1-(3-chlorobenzyl)-3-(2-fluoro-3-(trifluoromethyl)phenyl)urea (30). 1H NMR
(DMSO-d6): δ 4.35 (2H, d, J = 6.0 Hz), 7.22 (1H, t, J = 5.5 Hz), 7.32 (4H, m), 7.39 (2H,
m), 8.43 (1H, m), 8.76 (1H, s). RP-HPLC: tR = 6.87 min. ESI-MS m/z: 369.0 [M + Na]+.
Mp: 152-153°C.

55

1-(2-adamantyl)-3-(2,3,4-trifluorophenyl)thiourea (31). In a round bottom flask
equipped with a stir bar, 2-adamantanamine (0.238 g, 1.27 mmol) was dissolved in 10
mL of anhydrous dichloromethane. To this solution, 2,3,4-trifluorophenyl isothiocyanate
(0.14 mL, 1.06 mmol) followed by triethylamine (0.53 mL, 3.80 mmol) was added. The
reaction was stirred at room temperature overnight. The solvent was removed by rotary
evaporation. The resulting residue was purified by flash chromatography using a
petroleum ether to ethyl acetate gradient to elute the final compound (0.330 g, 92%). 1H
NMR (DMSO-d6): δ 1.62 (2H, d, J = 12.0 Hz), 1.81 (10H, m), 2.01 (2H, s), 4.33 (1H, s),
7.27 (1H, q, J = 9.5 Hz), 7.66 (1H, s), 8.19 (1H, s), 9.30 (1H, s). RP-HPLC: tR = 7.10
min. ESI-MS m/z: 363.1 [M + Na]+. Mp: 176-179 °C.
2-adamantyl 2,3,4-trifluorophenylcarbamate (32). In a round bottom flask equipped
with a stir bar, 2-adamantanol (0.422 g, 2.77 mmol) was dissolved in 10 mL of anhydrous
dichloromethane. To this solution, 2,3,4-trifluorophenyl isocyanate (2.79 mL, 2.31 mmol)
followed by triethylamine (1.15 mL, 8.32 mmol) was added. The reaction was stirred at
room temperature overnight. The solvent was removed by rotary evaporation. The
resulting residue was purified by flash chromatography using a petroleum ether to ethyl
acetate gradient to elute the final compound (0.727 g, 97%). 1H NMR (DMSO-d6): δ
1.54 (2H, d, J = 11.7 Hz), 1.78 (10H, m), 2.00 (1H, s), 4.78 (1H, s), 7.28 (1H, q, J = 9.6
Hz), 7.45 (1H, m), 9.46 (1H, s). RP-HPLC: tR = 7.40 min. ESI-MS m/z: 348.1 [M + Na]+.
Mp: 114-116 °C.
1-(2-adamantyl)-3-methyl-3-(2,3,4-trifluorophenyl)urea (33). To a round bottom flask
containing 1 (0.20 g, 0.617 mmol), anhydrous THF (10 mL) was added under argon. The
solution was then cooled to -78°C. To the cold solution, n-butyl lithium (0.385 mL,
0.617 mmol) was added drop wise and allowed to stir at -78°C for 10 min. To this
solution, iodomethane (0.038 mL, 0.617 mmol) was added drop wise at -78°C. The
solution was then allowed to warm to room temperature and then refluxed for 24 hrs.
The solvent was then removed by rotary evaporation. The resulting residue was purified
by flash chromatography using a petroleum ether to ethyl acetate gradient to elute the
final compound as an oil (0.192 g, 92%). 1H NMR (DMSO-d6): δ 1.45 (2H, d, J = 12.0
Hz), 1.73 (10H, m), 1.86 (2H, s), 3.14 (3H, s), 370 (1H, s), 5.62 (1H, d, J = 5.5 Hz), 7.26
(1H, m), 7.34 (1H, q, J = 9.0 Hz). RP-HPLC: tR = 7.10 min. ESI-MS m/z: 361.2 [M +
Na]+.
1-(2-adamantyl)-1,3-dimethyl-3-(2,3,4-trifluorophenyl)urea (34). To a round bottom
flask containing 1 (0.40 g, 1.23 mmol), anhydrous THF (25 mL) was added under argon.
The solution was then cooled to -78°C. To the cold solution, n-butyl lithium (1.54 mL,
2.47 mmol) was added drop wise and allowed to stir at -78°C for 10 min. To this
solution, iodomethane (0.154 mL, 2.47 mmol) was added drop wise at -78°C. The
solution was then allowed to warm to room temperature and then refluxed for 24 hrs.
The solvent was then removed by rotary evaporation. The resulting residue was purified
by flash chromatography using a petroleum ether to ethyl acetate gradient to elute the
final compound (0.190 g, 44%). 1H NMR (DMSO-d6): δ 1.51 (2H, d, J = 12.5 Hz), 1.74
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(10 H, m), 2.18 (2H, s), 2.66 (3H, s), 3.11 (3H, s), 3.61 (1H, s), 7.23 (1H, m), 7.38 (1H, q,
J = 9.5 Hz). RP-HPLC: tR = 7.42 min. ESI-MS m/z: 375.1 [M + Na]+. Mp: 71-74 °C.
1-(2-adamantyl)-3-(4-methoxyphenyl)urea (35). 1H NMR (DMSO-d6): δ 1.57 (2H, d, J
= 12.5 Hz), 1.79 (12H, m), 3.70 (3H, s), 3.76 (1H, d, J = 8.0 Hz), 6.34 (1H, d, J = 8.0
Hz), 6.82 (2H, d, J = 8.5 Hz), 7.28 (2H, d, J = 9.0 Hz), 8.20 (1H, s). RP-HPLC: tR = 6.62
min. ESI-MS m/z: 301.2 [M + H]+. Mp: 125-128 °C.
Methyl 4-(3-(1-adamantyl)ureido)-2-hydroxybenzoate (36). In a round bottom flask
equipped with a stir bar, 4-amino-2-hydroxy benzoic acid (5.0 g, 32.67 mmol) was
dissolved in 50 mL of anhydrous methanol. To this solution concentrated sulfuric acid (7
mL) was added. This solution was allowed to reflux overnight. The solution was
allowed to cool to room temperature and then sodium bicarbonate was stirred with the
solution until gas evolution ceased. The sodium bicarbonate was then filtered off and the
solution concentrated by rotary evaporation. The methyl ester was purified by flash
chromatography using a hexane to ethyl acetate gradient to elute the purified product (3.0
g, 55%). The methyl ester (1.204 g, 7.2 mmol) was then taken back up in anhydrous
dichloroethane (10 mL) and 1-adamantyl isocyanate (1.064 g, 6.0 mmol) added. The
solution was refluxed for 4 days. Pure Lee 1392 (0.85 g, 41%) was obtained by using
flash chromatography with a hexane to ethyl acetate gradient. 1H NMR (CDCl3): δ 1.68
(6H, s), 2.05 (9H, m), 3.90 (3H, s), 4.73 (1H, s), 6.62 (1H, s), 6.83 (1H, s), 6.98 (1H, d, J
= 9 Hz), 7.70 (1H, d, J = 8.5 Hz), 10.83 (1H, s). RP-HPLC: tR = 6.82 min. ESI-MS m/z:
367.1 [M + Na]+. Mp: 207-210 °C.
1-(1-adamantyl)-3-(2-ethoxyethyl)urea (37). 1H NMR (CDCl3): δ 1.23 (3H, t, J = 7.0
Hz), 1.69 (6H, s), 1.98 (6H, s), 2.09 (3H, s), 3.33 (2H, q, J = 5.0 Hz), 3.52 (4H, m), 4.41
(1H, s), 4.56 (1H, s). ESI-MS m/z: 289.1 [M + Na]+. Mp: 116-118 °C.
1-(1-adamantyl)-3-(3-methoxypropyl)urea (38). 1H NMR (CDCl3): δ 1.69 (6H, s), 1.77
(2H, quintet, J = 6.0 Hz), 1.98 (6H, s), 2.09 (3H, s), 3.25 (2H, q, J = 6.0 Hz), 3.36 (3H, s),
3.49 (2H, t, J = 5.5 Hz). ESI-MS m/z: 289.3 [M + Na]+. Mp: 135-137 °C.
1-(1-adamantyl)-3-(2-isopropoxyethyl)urea (39). 1H NMR (CDCl3): δ 1.18 (6H, d, J =
6.0 Hz), 1.68 (6H, s), 1.98 (6H, s), 2.08 (3H, s), 3.30 (2H, q, J = 5.5 Hz), 3.50 (2H, t, J =
5 Hz), 3.61 (1H, m), 4.50 (1H, s), 4.61 (1H, s). ESI-MS m/z: 281.5 [M + H]+. Mp: 92-95
°C.
1-(1-adamantyl)-3-(2-propoxyethyl)urea (40). 1H NMR (CDCl3): δ 0.95 (3H, t, J = 7.5
Hz), 1.62 (2H, m), 1.69 (6H, s), 1.98 (6H, s), 2.09 (3H, s), 3.33 (2H, q, J = 5.0 Hz), 3.42
(2H, t, J = 6.5 Hz), 3.50 (2H, t, J = 5.0 Hz), 4.39 (1H, s), 4.54 (1H, s). ESI-MS m/z:
303.1 [M + Na]+. Mp: 87-90 °C.
1,1-bis(tetrahydro-2H-pyran-4-yl)-3-(2,3,4-trifluorophenyl)urea (41). 1H NMR
(CDCl3): δ 1.69 (4H, d, J = 10.5 Hz), 2.17 (4H, m), 3.50 (4H, t, J = 11 Hz), 3.89 (2H, m),
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4.10 (4H, m), 6.45 (1H, s), 6.96 (1H, q, J = 9.5 Hz), 7.78 (1H, m). RP-HPLC: tR = 5.58
min. ESI-MS m/z: 359.3 [M + H]+. Mp: 191-193 °C.
1,3-bis(4-(isopentyloxy)phenyl)urea (42). To a round-bottom flask, 4-nitrophenol (2.0
g, 14.37 mmol) and sodium hydroxide (1.73 g, 43.13 mmol), was dissolved in N,Ndimethylformamide (50 mL). The solution was stirred at room temperature for 15 min.
After stirring, 1-bromo-4-methylpentane (5.39 mL, 43.43 mmol) was added to the
solution and refluxed for 3 h. The resulting solution was washed with 0.7 N HCl (3 20
mL) then extracted with diethyl ether (3 20 mL). The combined organic fractions were
then washed with brine (3 20 mL) and dried over magnesium sulfate. The solution was
then filtered and the solvent by using rotary evaporation. The crude mixture was then
purified by flash chromatography using a petroleum ether to ethyl acetate gradient to
obtain pure intermediate (2.69 g, 90%). The intermediate nitro compound was then
converted to an aniline by hydrogenation using Pd/C catalyst overnight. The aniline was
used in the next step without further purification (1.85 g, 80%). In a round bottom flask,
the aniline (1.27 g, 7.08 mmol) was dissolved in dichloromethane and then triethylamine
(1.97 mL, 14.16 mmol) was added and the solution was allowed to stir at room
temperature for 15 min. In a separate round bottom flask, triphosgene (0.70 g, 2.36
mmol) was dissolved in dichloromethane. Then the solution of the aniline was slowly
added into the solution of thiophosgene under argon and allowed to stir overnight at room
temperature. The product (0.301 g, 33%) crashed out of solution and was filtered off and
washed with dichloromethane. 1H NMR (DMSO-d6): δ 0.93 (12H, d, J = 6.5 Hz), 1.59
(4H, q, J = 6.5 Hz), 1.77 (2H, m), 3.94 (4H, t, J = 6.5 Hz), 6.85 (4H, d, J = 9.0 Hz), 7.31
(4H, d, J = 9.0 Hz), 8.35 (2H, s). RP-HPLC: tR = 7.44 min. ESI-MS m/z: 407.3 [M +
Na]+. Mp: 173-175 °C.
1,3-bis(4-(isopentyloxy)phenyl)thiourea (43). To a round-bottom flask, 4-nitrophenol
(2.0 g, 14.37 mmol) and sodium hydroxide (1.73 g, 43.13 mmol), was dissolved in N,Ndimethylformamide (50 mL). The solution was stirred at room temperature for 15 min.
After stirring, 1-bromo-4-methylpentane (5.39 mL, 43.43 mmol) was added to the
solution and refluxed for 3 h. The resulting solution was washed with 0.7 N HCl (3 20
mL) then extracted with diethyl ether (3 20 mL). The combined organic fractions were
then washed with brine (3 20 mL) and dried over magnesium sulfate. The solution was
then filtered and the solvent by using rotary evaporation. The crude mixture was then
purified by flash chromatography using a petroleum ether to ethyl acetate gradient to
obtain pure intermediate (2.69 g, 90%). The intermediate nitro compound was then
converted to an aniline by hydrogenation using Pd/C catalyst overnight. The aniline was
used in the next step without further purification (1.85 g, 80%). In a round bottom flask,
the aniline (1.85 g, 10.9 mmol) was dissolved in dichloromethane and then triethylamine
(2.88 mL, 20.64 mmol) was added and the solution was allowed to stir at room
temperature for 15 min. In a separate round bottom flask, thiophosgene (0.26 mL, 3.44
mmol) was dissolved in dichloromethane. Then the solution of the aniline was slowly
added into the solution of thiophosgene under argon and allowed to stir overnight at room
temperature. The product (0.683 g, 50%) crashed out of solution and was filtered off and
washed with dichloromethane. 1H NMR (DMSO-d6): δ 0.94 (12H, d, J = 7.0 Hz), 1.61
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(4H, q, J = 7.0 Hz), 1.79 (2H, m), 3.98 (4H, t, J = 7.0 Hz), 6.90 (4H, d, J = 9.0 Hz), 7.10
(4H, d, J = 9.0 Hz), 9.45 (2H, s). RP-HPLC: tR = 7.39 min. ESI-MS m/z: 423.2 [M +
Na]+. Mp: 139-141 °C.
MIC Determination
MIC values were determined against M. tuberculosis (H37Rv) and other bacteria
by the microbroth dilution method.108,109 A broth culture of M. tuberculosis or M.
smegmatis mc2155 was grown in Middlebrook 7H9 medium with 10% ADC supplement
to an OD600 of 0.4–0.6. The culture was diluted with 7H9 medium to an OD600 of 0.01,
and 100µL was added to a microtiter plate containing two-fold serial dilutions of the
tested compounds for a final volume of 200µL. The plates were incubated at 37 C for 7
days. The MIC90 was determined by visual inspection and defined as the concentration
that inhibited 90% of growth. MICs against other bacteria were performed according to
the CLSI method and also read by visual inspection.110,111
Cytotoxicity Study
Cytotoxicity assays were performed using the Vero monkey kidney cell line
(CCL-81) obtained from the American Type Culture Collection (ATCC, Manassas, VA).
Vero cells were propagated in Dulbecco’s Modified Eagle’s Medium supplemented with
10% fetal bovine serum and maintained in a humidified incubator (37°C, 5% CO2). After
dislodging cells with a cell scraper, they were collected by centrifugation, resuspended in
fresh medium at ~106 cells/mL, dispensed into 96-well microtiter plates (100 µl/well) and
incubated for 18 h at 37°C before being used for cytotoxicity assays. Test compounds
were subsequently added at concentrations ranging from 400-0.2 µg/mL and incubation
continued for another 72 h before the cytopathic effects of compounds was determined
using the MTT Cell Proliferation Assay (ATCC). The cytotoxic IC50 defined as the
concentration causing 50% reduction in Vero cell viability, was obtained from a dose
response curve plotted from percentage activity versus log10 concentration. Therapeutic
selectivity was then determined as the Cytotoxic IC50 divided by the MIC against M.
tuberculosis.
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CHAPTER 3: DESIGN OF NOVEL SIDEROPHORE ANTIMICROBIAL
AGENTS FOR THE TREATMENT OF GRAM-NEGATIVE BACTERIA
Introduction to Gram-Negative Bacteria

Composition
Gram-negative bacterial infections are much more difficult to treat than grampositive bacterial infections. This discrepancy is due to a variety of reasons that
ultimately lead back to the fact that penetrating the gram-negative bacterial cell wall is
very difficult for drug-like molecules when compared to gram-positive bacteria. Gramnegative bacteria have a unique outer membrane, a thinner peptidoglycan layer, and a
periplasmic space between the cell wall and the membrane. In the outer membrane,
gram-negative bacteria have lipopolysaccharides, porin channels, and murein lipoprotein
all of which gram-positive bacteria lack that limit permeability.112
Quorum Sensing
Quorum sensing is a term that is used to describe the ability of a population of
unicellular bacteria to act as a multicellular organism in a cell-density-dependent
manner.113-115 Bacteria use small diffusible molecules to exchange information between
the separate organisms. These small molecules are called “quormones,” or autoinducers.
One important class of quormones used by gram-negative bacteria is the family of Nacylhomoserine lactones (AHLs). The length of the acyl chain and the oxidation state of
the AHLs provide for bacterial strain specificity in the signaling process and the
subsequent synchronization of gene expression.116 Depending upon the pattern of
acylation, most AHLs will diffuse freely across the bacterial cell membrane. Upon
reaching a critical threshold concentration, the AHLs bind to their respective receptor
proteins triggering the expression of target genes; for example, in Vibrio fischeri, genes
located on the lux operon are transcribed that are responsible for the production of
bioluminescence.117
Pseudomonas aeruginosa is a common environmental microorganism that has
obtained the ability to take advantage of weaknesses in their host’s immune system to
become an opportunistic pathogen in humans.118 Pseudomonas aeruginosa is an
important pathogen for patients with cystic fibrosis. Due to the nature of cystic fibrosis,
infections caused by Pseudomonas aeruginosa, if left untreated, in these patients is often
fatal. Pseudomonas aeruginosa can also manifest itself as a nosocomial infection in
other immuno-suppressed populations, particularly in burn victims. These infections
cause serious complications because of their wide array of virulence mechanisms and
high inherent antibiotic resistance to Pseudomonas aeruginosa. These infections
continue to become more perilous as the bacteria continues to grow and form biofilms
that increase resistance to many antibiotics.116
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A significant amount of research has been done over the past 10 years in
elucidating the molecular mechanisms underlying the pathogenicity of Pseudomonas
aeruginosa. Two different AHLs, N-(3-oxododecanoyl)homoserin lactone (1),
synthesized by LasI, and N-butyrylhomoserine lactone (2), synthesized by RhlI, have
been identified as the main quorum-sensing molecules in Pseudomonas aeruginosa
(Figure 3.1).119 Quorum sensing has been demonstrated to control the expression of other
virulence factors as well as the formation of biofilms.120 It has been demonstrated that N(3-oxododecanoyl)homoserine lactone (1) itself and its tetramic acid-degradation
product, derived from an unusual intramolecular condensation reaction, function as innate
bactericidal agents. Also, the AHL degradation product has been shown to tightly
coordinate essential metals such as iron, possibly providing a previously unrecognized
primordial siderophore.116 The iron chelating ability of tetramic acids has been proven
and quantified.121
Tetramic Acids

Tetramic acids are a known class of antibacterial compounds.116,122 The term was
coined in 1901 in reference to the heterocyclic 1,5-dihydro-4-hydroxy-2H-pyrrol-2-one
system, 3 (Figure 3.2). This structure is a tautomer of 2,4-pyrrolidinedinone, which is the
major tautomeric species in solution, 4 (Figure 3.2). Compounds containing this
functionality show a wide range of biological activity and have attracted the attention of
medicinal chemists who hope to utilize this unique group in the design of future
antibacterial agents.122
Naturally occurring tetramic acids have stirred up a great amount of interest due
to their wide array of antibacterial activity. However, there currently are not any drugs
available on the market that contain the tetramic acid core.123,124 The tetramic core is the
key component of many natural products such as reutericyclin, tenzuazoic acid,
streptolydigin, PF1052, and erythroskyrine (Figure 3.3).124-127 All of these compounds
show antibacterial activity. Quite a few studies have been conducted on synthesizing and
isolating naturally occurring tetramic acids. However, only a few studies exist that report
on the SAR of these compounds and emphasize their antibacterial properties.128-130
Synthesis of Quorum Sensing Molecule 1 and Its Degradation Product

In order to test the iron chelating ability of the tetramic acid degradation product
of N-(3-oxododecanoyl)homoserine lactone, both compounds were synthesized (Scheme
3.1).116,131 Compound 1 was prepared by the DCCI/DMAP catalyzed acylation of
Meldrum’s acid with decanoic acid in dichloromethane. The isolated product was used in
the next step of the reaction without further purification. Amidation of the product with
L-homoserine lactone in the presence of triethylamine in acetonitrile afforded the desired
N-(3-oxododecanoyl)homoserine lactone in 9% yield.
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The tetramic acid degradation product of 1 was prepared by placing 1 in a flask
containing anhydrous methanol. To this a 0.5 molar (M) solution of sodium methoxide in
methanol was added. This reaction was stirred at room temperature, and then passed
through an acidic ion-exchange resin (Dowex 50WX2-200) and eluted with methanol.
The filtrates were combined and concentrated. The final product was afforded after
purification via HPLC. The final compound was obtained in 35% yield.
Significance of the Tetramic Acid Degradation Product as a Siderophore

Compound 1 and its tetramic acid degradation product play a pivotal in the life of
the gram-negative bacteria Pseudomonas aeruginosa. It has been hypothesized that due
to the fact compound 1 is the primary quorum sensing molecule for Psuedomonas
aeruginosa, and the fact that tetramic acids have proven antibacterial activity, the
tetramic acid of 1 plays an important role in bacterial viability.116 One study has shown
that lipid-like antibiotics have a propensity to localize near the cell surface on grampositive bacteria.132 It has been shown that when the tetramic acid of 1 is incubated
overnight with gram-positive bacteria, significant antibacterial activity is seen. However,
when the same experiment is conducted with gram-negative bacteria, no antibacterial
activity was seen.116 In analogous studies, it has been shown that structurally similar
tetramic acids also show toxicity against gram-positive bacteria with little variation in
EC50 value across different species and genera.133 While the antibacterial activity of this
tetramic acid may not be as great as other known bactericidal agents, the fact that this
compound is nonenzymatically produced from a cell-cell signaling molecule is
significant.116
These compounds were synthesized in an attempt, not to demonstrate their
antibacterial activity, but to show the iron chelating ability of the tetramic acid in our
hands, and its potential role as a siderophore. It has been shown that tetramic acids have
the ability to chelate iron in an efficient manner. Iron has an indispensable function in
physiological processes and pathogenesis of bacteria.134,135 Some bacteria have been
known to synthesize a siderophore to aid in the sequestration of iron, an element that is
essential for their growth, but is poorly soluble at physiological conditions.136 It has been
shown that Pseudomonas aeruginosa produces two siderophores, pyoverdin and
pyochelin, and can also utilize various heterologous siderophores of microbial origins.134
The genome of Pseudomonas aeruginosa encodes for numerous homologues of ironsiderophore receptor genes. This reveals just how important iron is to bacterial survival,
and its need to compete with other microorganisms within their environment for this
indispensable metal.137,138
The tetramic acid iron chelate of compound 1 has been sent to collaborators at
Northeastern University to explore its potential as a growth promoter for unculturable
gram-negative organisms. This group of collaborators are conducting biological
evaluations of this compound, which are currently still in their infancy. There has been
some promising preliminary data that has arisen from these tests. The collaborators
collected intertidal sediment from Canoe Beach in Nahant, MA and air dried it to enrich
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for spore forming microorganisms. The 5 g of sediment was mixed with 5 mL of 2%
Artificial Sea Salts (Sigma) and vortexed for 1 minute to remove bacterial cells from the
sand biofilm. Next, 100 uL samples were plated on R2A (Difco) agar supplemented with
2% Artificial Sea Salts. Replicates with and without spotting 10 uL of a 0.24 mg/mL
solution of tetramic acid of compound 1 (1% DMSO in water) were incubated at room
temperature and photographed after one and three days.
This preliminary data clearly shows that while it takes three days for most
colonies to appear from these bacterial isolates, the largest and fastest growing colony
appears where the tetramic acid of compound 1 was spotted (Figure 3.4). The experiment
was performed induplicate, and the results were identical for both runs (Figure 3.5). This
data shows the ability of the tetramic acid of compound 1 to presumably aid in the
sequestration of nutrients from the environment surrounding these bacteria. This allows
the bacterial colony to grown larger and more rapidly than the other colonies on the
plates. This data clearly demonstrates the ability of bacteria to adapt and use foreign
substances in order to provide itself with the best opportunity to survive.
The 3-acetyl-pyrrolidine-2,4-dione heterocycle core found in most tetramic acid,
including the tetramic acid of compound 1, has been shown to effectively chelate
numerous metal cations including iron.121 It is unclear as to whether chelation with a
metal cation alters the toxicity of this compound as some tetramic acids have shown an
increased toxicity upon chelation while others have shown a decrease in toxicity.139
Previous studies have demonstrated that the fungal tetramic acid metabolite tenuazoic
acid forms an octahedral complex with a 3:1 stoichiometry upon chelation with
iron(III).140 In accordance with these studies, it is hypothesized that the tetramic acid of
compound 1 will have the same coordination geometry and stoichiometry.116
Synthesis of Iron(III) Chelation Product of Tetramic Acids

The iron(III) chelation complex of tetramic acid from compound 1 was
synthesized by dissolving three equivalents of the tetramic acid in methanol (Scheme
3.2). As the tetramic acid dissolved, the solution became a light tan color. Separately,
one equivalent of iron(III) chloride was dissolved in methanol. This solution was bright
yellow in color. The solution of iron(III) chloride was then added to the solution of the
tetramic acid and the resulting solution immediately became dark red in color. The
solutions were stirred at room temperature for 30 minutes, and then concentrated by
rotary evaporation to afford a dark red viscous liquid. The formation of the 3:1 ratio was
confirmed via mass spectrometry and spectrophotometric assay at 440 nm. A chelation
complex was also synthesized for another tetramic acid derivative that was previously
synthesized, Lee 867 (Scheme3.3). This product was obtained utilizing the same
synthetic procedure for the first chelation complex.
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Figure 3.4:

Preliminary Biological Evaluation of Tetramic Acid 1

Figure 3.5:

Repeat of Preliminary Biological Evaluation of Tetramic Acid 1
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Scheme 3.2: Synthesis of Chelation Product for Tetramic Acid 1
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Scheme 3.3: Synthesis of Chelation Complex for Lee 867
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Siderophores as Antibacterial Agents

Background
As previously discussed, iron plays a vital role in the life of all bacteria.
However, due to the nature of the element it is not readily available at physiological
conditions. That is due to the fact that it is rapidly oxidized from Fe2+ to Fe3+ and
subsequently forms insoluble hydroxides. The concentration of Fe3+ at physiological
conditions is as low as 10-9 M, which makes this commodity very scarce for the
bacteria.141-143 Bacteria have evolved numerous ways to overcome this shortage of
iron.144,145 These evolutionary tactics primarily involve the formation of receptor proteins
on the surface of the bacteria that bind to a wide range of iron-containing molecules.
These receptors caused the iron complexes to become localized on the cell surface, where
they then become accessible for transport inside the cell. This process is easily carried
out by gram-positive bacteria. They are able to deliver the siderophore to Adenosine
Triphosphate (ATP)-binding-cassette (ABC) importers, which transport the siderophore
across the cell membrane. The energy for this process comes from the hydrolysis of ATP
inside of the cell. A process similar to this occurs in the gram-negative bacteria, but the
process is more convoluted due to the presence of the additional lipid layer found in these
organisms.143
Transportation of nutrients in gram-negative bacteria usually occurs via porins.
These porins allow small molecules and ions to diffuse through the membrane. However,
this diffusion-driven process is inefficient for the supply of iron that is necessary for cell
survival. The inefficiency arises primarily due to the extremely low concentration of iron
in the surrounding environment.143
TonB Transport System
Gram-negative bacteria have evolved a method which allows them to overcome
the inefficiency of porin diffusion in order to obtain nutrients in a much more efficient
manner. This sophisticated method enables the bacteria to supply high-affinity outermembrane receptors with the necessary energy for ligand uptake from the cytoplasmic
membrane by the protein complex known as the Ton system.143,146-149 This complex
consists of numerous proteins, including TonB. TonB is said to experience a series of
conformational changes that are driven by the proton-motive force, which allows it
mechanically interact with the outer-membrane receptors, thus enabling transport into the
interior of the cell.
The importance of TonB has been validated by numerous scientific studies that
elucidated the fact that TonB plays a vital role in nutrient transport. These studies
showed that TonB mutants were unable to transport siderophores or vitamin B12 into the
cell.150,151 Another important experiment, conducted in 1980, showed that BtuC mutants,
which are unable take up vitamin B12 across the cytoplasmic membrane, were able to
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generate a 1000-fold increase in the concentration of vitamin B12 in the periplasmic
space, when compared to the external medium, as long as the TonB and it energy source
were in place.152 Therefore, while the mechanism for the TonB pathway may not be
entirely elucidated, it is shown to play a vital role in the uptake of nutrients from the
cellular environment.
Application
As stated previously, there is an ever increasing need to develop novel antibiotics
for the treatment of gram-negative bacterial infections. Of particular concern is the
organism Pseudomonas aeruginosa, it posses intrinsic resistance to numerous currently
used antibiotics and it has also acquired additional mechanisms of resistance, including
target mutations, increased expression of efflux pumps and of antibiotic-degrading
enzymes.153 One of the biggest problems associated with treating gram-negative bacteria
is getting the drug inside of the bacteria. As discussed previously, gram-negative
bacteria, Pseudomonas aeruginosa in particular, have evolved numerous ways in which
to get nutrients from the environment into their interior for use. Since the 1980s,
numerous attempts have been made by drug developers to take advantage of this fact and
utilize siderophore containing antibiotics in hopes to gain entry into the bacteria.154 One
such agent is BAL30072 (Figure 3.6).
BAL30072 is a novel siderophore monobactam antibiotic that is currently in preclinical trials. It contains a monobactam antibiotic, which is analogous to the agent
tigemonam, and a dihydropyridone iron-chelating group.155,156 It has been shown that
this combination of features provides markedly different antibiotic properties to
BAL30072, along with a different mechanism of action.155,157,158 BAL30072 has shown
activity against 70% of the carbapenem-resistant Enterobacteriaceae strains tested,
including stains with class A, class B, and class D carbapenemases. BAL30072 show
promising activity against non-fermentors, especially Acinetobacter spp., Burkholderia
spp., and Stenotrophomonas maltophila. It was also the most active β-lactam against
MDR-Pseudomonas aeruginosa in the panel tested.159
The promising activity shown by BAL30072 has led to the development of a
hypothesis involving the use of a novel siderophore attached to an antibacterial agent
(Figure 3.7). It is thought that, as in the case of BAL30072, this siderophore will allow
the antibacterial agent to enter the gram-negative bacteria via an alternate route with
more efficacy than porin mediated entry, thus allowing the agent to kill the bacteria more
effectively. The siderophore that was chosen for this experiment was the tetramic acid
core. As previously shown, this core structure can readily chelate iron and therefore
shows promise for utilization as a siderophore.
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Synthesis of Tetramic Acid Core

The tetramic acid core was synthesized according to a previously reported
procedure (Scheme 3.4).124 The synthesis started with the reductive amination of valine
ethyl ester hydrochloride salt with 3-((tert-butyldimethylsilyl)oxy)propanal in
tetrahydrofuran in the presence of magnesium sulfate and triethylamine. The resulting
imine was reduced using sodium borohydride in methanol. The secondary amine was
then reacted with diketene in dichloromethane in the presence of triethylamine at reflux
to yield the β-keto amide.160 The amide was then cyclized in the tetramic acid core using
Amberlyst A-26 hydroxide resin.161,162
The starting aldehyde (3-((tert-butyldimethylsilyl)oxy)propanal) is a relatively
expensive compound. Therefore, in order to reduce the cost associated with using this
starting material; an alternate synthetic route was developed (Scheme 3.5). This route
utilizes the same valine ethyl ester hydrochloride salt, but instead of the aldehyde, (3bromopropoxy)(tert-butyl)dimethylsilane was used in its place. The reaction was carried
out in the microwave reactor in dimethylformamide in the presence of potassium
carbonate. Once the secondary amine was isolated, the reaction continued in the same
manner as shown in Scheme 3.4.
This multiple-step synthetic reaction afforded the final compound and the desired
intermediates in adequate yields. The first step of this reaction produced the secondary
amine intermediate in a 44% yield. The second step afforded the amide in a 50% yield.
The final step provided the final product in an 88% yield. Overall these yields are
reasonable and are high enough to provide a substantial amount of the final compound in
a reasonable timeframe. When attempting to couple the tetramic acid core to the desired
antibiotic, in order to complete the desired synthesis, problems were noted and no final
compound was obtained. A number of different synthetic techniques were attempted, but
none were able to afford the desired compound. One problem may be the fact that there
are two alcohol moieties present in the tetramic acid core. Upon trying to couple the
primary alcohol to the antibiotic, no reaction was observed. This is probably due to the
fact that the secondary alcohol may be interfering with the reaction. In order to alleviate
this problem, orthogonal protecting group strategies need to be explored that can provide
selective protection for each type of alcohol present. Upon attempting various other
synthetic methodologies, none were able to produce the desired final compound.
Conclusions

This project is only in its infancy, and there is much left to discover. There is still
much work to be done involving the use of siderophores as aids in the design of novel
antimicrobial agents. The large literature precedence for this type of work is very
promising. I feel as though the work done on this project in our hands will only help to
further elucidate the role of siderophores, in particular the role of tetramic acids, in how
they alter the in vitro and in vivo efficacy of antibacterial agents. The preliminary
biological study conducted by our collaborators at Northeastern University provides
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Scheme 3.4: Synthesis of Tetramic Acid Core
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much hope for our hypothesis that this particular type of siderophore will be useful in
providing a route by which an antibiotic can easily enter the gram-negative bacteria. It is
obvious that much more work needs to be done in order to truly validate this study.
However, this project appears to be headed down a path that will yield a very fruitful
study into the intricacies of designing effective gram-negative antibacterial agents.
Experimental Section

All anhydrous solvents and starting materials were purchased from Aldrich
Chemical Co. (Milwaukee, WI). All reagent grade solvents used from chromatography
were purchased from Fisher Scientific (Suwanee, GA) and flash column chromatography
silica cartridges were obtained from Biotage Inc. (Lake Forest, VA). The reactions were
monitored by thin-layer chromatography (TLC) on pre-coated Merch 60 F254 silica gel
plates and visualized using ultraviolet (UV) light (254 nm). A Biotage FLASH column
chromatography system was used to purify mixtures. All 1H nuclear magnetic resonance
(NMR) spectra were recorded on a Varian INOVA-500 spectrometer. Chemical shifts (δ)
are reported in parts per million relative to the residual solvent peak or internal standard
(tetramethylsilane), and coupling constants (J) are reported in hertz (Hz). Mass spectra
were recorded on a Bruker Esquire liquid-chromatography mass-spectrometer using
electrospray ionization. Purity of the products was confirmed before testing by analytical
reverse phase-high performace liquid chromatography on a Shimadzu high-performance
liquid-chromatography system, and all final compounds had a purity of 95% or greater as
determined by RP-HPLC. Gradient Conditions: solvent A (0.1% Trifluoroacetic Acid
(TFA) in water) and solvent B (acetonitrile): 0-2.00 min 100& A, 2.00-7.00 min 0-100%
B (linear gradient), 7.00-8.00 min 100% B, UV detection at 254 nm.
N-(3-oxododecanoyl)-l-homoserine lactone (1). To an anhydrous dichloromethane
solution (20 mL) containing decanoic acid (0.57 mL, 4 mmol) was added 4(dimethylamino)pyridine (0.513 g, 4.2 mmol), N,N’-dicyclohexylcarbodiimide (0.907 g,
4.4 mmol), and Meldrum’s acid (0.576 g, 4 mmol). This solution was stirred at room
temperature overnight and then filtered to remove the precipitated N,N’dicyclohexylurea. The filtrate was evaporated to dryness, and the residue was
redissolved in ethyl acetate. The ethyl acetate solution was washed with 2 M
hydrochloric acid, dried over anhydrous magnesium sulfate, and concentrated to afford
the acylated Meldrum’s acid, which was used without purification in the next step of the
reaction. To a stirred solution of the acylated Meldrum’s acid (1.05 g, 3.5 mmol) in
acetonitrile (30 mL) was added to l-homserine lactone hydrochloride (0.482 g, 3.5 mmol)
and triethylamine (0.585 mL, 4.2 mmol). The mixture was stirred at room temperature
for 2 hours and then heated under reflux conditions for 3 hours. The solvent was
removed by rotary evaporation to give a residue that was redissolved in ethyl acetate.
The organic solution was subsequently washed with saturated sodium hydrogen
carbonate solution, 1 M potassium hydrogen sulfate solution, and saturated sodium
chloride solution. After drying over anhydrous magnesium sulfate, the organic solution
was evaporated and the residue was purified flash chromatography using a hexanes to
ethyl acetate gradiant to afford pure 1 (0.108 g, 9%). 1H NMR (CDCl3): δ 0.88 (3H, t, J
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= 7.5 Hz), 1.26 (12 H, m), 1.59 (2H, m), 2.24 (1H, pentet, J = 11 Hz), 2.53 (2H, t, J = 7.5
Hz), 2.75 (1H, pentet, J = 1.5 Hz), 3.50 (2H, s), 4.28 (1H, m), 4.48 (1H, t, J = 8 Hz), 4.59
(1H, m), 7.75 (1H, s). RP-HPLC: tR = 7.68 min. ESI-MS m/z: 320.2 [M + Na]+.
3-(1-hydroxydecylidene)-5-(2-hydroxyethyl)pyrrolidine-2,4-dione (Tetramic Acid of
1). To a flask containing N-(3-oxododecanoyl)-l-homoserine lactone (0.090 g, 0.3026
mmol) in anhydrous methanol (1 mL), sodium methoxide in methanol (0.5 M, 0.605 mL,
0.3026 mmol) was added at room temperature under argon. After stirring at 55 degrees C
for three hours, the reaction mixture was passed through acidic ion-exchange resin
(DOWEX 50WX2-200) and eluted with methanol (20 mL). The combined filtrates were
concentrated on a rotary evaporated to give a residue. The resulting residue was purified
using RP-HPLC to afford pure compound (0.020 g, 22%). 1H NMR (CD3OD): δ 0.90
(3H, t, J = 7.0 Hz), 1.23-1.43 (12 H, m), 1.66 (2H, m), 1.72-1.83 (1H, m), 1.96-2.10 (1H,
m), 2.70-2.92 (2H, m), 3.61-3.79 (2H, m), 3.99 (1H, s). RP-HPLC: tR = 6.708 min. ESIMS m/z: 320.1 [M + Na]+.
Iron(III) Chelate of 3-(1-hydroxydecylidene)-5-(2-hydroxyethyl)pyrrolidine-2,4dione. A small round-bottom flask containing 3-(1-hydroxydecylidene)-5-(2hydroxyethyl)pyrrolidine-2,4-dione (0.050 g, 0.168 mmol) in methanol (1 mL) was
stirred at room temperature for 5 minutes. A separate round-bottom flask containing
iron(III) chloride (0.0091 g, 0.056 mmol) in methanol (1 mL) was stirred at room
temperature for 5 minutes. The solution of iron(III) chloride was then added to the flask
containing the solution of 3-(1-hydroxydecylidene)-5-(2-hydroxyethyl)pyrrolidine-2,4dione and this was allowed to stir at room temperature for 30 minutes. The content of the
flask was then concentrated to afford pure compound. ESI-MS m/z: 947.49 [M + 3H]+.
Iron(III) Chelate of Lee 867. A small round-bottom flask containing Lee 867 (0.0725
g, 0.215 mmol) in methanol (1 mL) was stirred at room temperature for 5 minutes. A
separate round-bottom flask containing iron(III) chloride (0.012 g, 0.072 mmol) in
methanol (1 mL) was stirred at room temperature for 5 minutes. The solution of iron(III)
chloride was then added to the flask containing the solution of Lee 867 and this was
allowed to stir at room temperature for 30 minutes. The content of the flask was then
concentrated to afford pure compound. ESI-MS m/z: 1068.31 [M + 3H]+.
(Z)-3-(1-hydroxyethylidene)-1-(3-hydroxypropyl)-5-isopropylpyrrolidine-2,4-dione
(Tetramic Acid Core). To a stirred solution of valine ethyl ester hydrochloride (0.408 g,
2.65 mmol) in tetrahydrofuran was added magnesium sulfate (0.543 g, 4.51 mmol), 3((tert-butyldimethylsilyl)oxy)propanal (1 g, 5.31 mmol), and triethylamine (0.37 mL,
2.65 mmol). The reaction was then allowed to stir at room temperature under argon for
five hours. The reaction mixture was then filtered and the eluent evaporated to give the
crude imine intermediate. The imine was directly redisolved in methanol, and sodium
borohydride (0.20 g, 5.31 mmol) was slowly added to the reaction mixture. The reaction
was stirred at room temperature for 30 minutes before being quenched with excess 1 N
sodium hydroxide and extracted with ethyl acetate. The ethyl acetate extracts were
combined, washed with brine, and dried over sodium sulfate. The extracts were then
concentrated under vacuum. The residue was purified by flash chromatography using a
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petroleum ether to ethyl acetate gradient. The purified intermediate (0.340 g, 1.17 mmol)
was then dissolved in dichloromethane. To this solution diketene (0.084 mL, 1.17 mmol)
and five drops of triethylamine were added. The resulting solution was then heated under
reflux conditions for six hours. The reaction mixture was then cooled, diluted with
dichloromethane and washed with dilute hydrochloric acid followed by water. The
dichloromethane fractions were then dried over sodium sulfate and concentrated. This
intermediate was then purified with flash chromatography using a petroleum ether to
ethyl acetate gradient. This intermediate (0.238 g, 0.593 mmol) was then dissolved in
methanol. To this solution Amberylyst A-26 resin (4.2 mequiv/g, 3 equiv) was added.
The reaction was stirred at room temperature under agron for two hours. The product
containing resin was then filtered and washed with methanol (3 x 10 mL). The resin was
then stirred at room temperature for 30 minutes in methanol (10 mL) with TFA (400 µL).
It was then filtered and washed with methanol. Concentration of the eluent afforded pure
product (0.126 g, 88%). 1H NMR (CDCl3): δ 0.93 (6H, d, J = 7.0 Hz), 1.71-1.77 (2H,
m), 2.05 (2.2H, s), 2.20 (0.8H, s), 2.64 (1H, m), 2.95 (2H, m), 3.52-3.60 (3H, m), 4.45
(1H, d, J = 7.0 Hz). RP-HPLC: tR = 6.13 min. ESI-MS m/z: 264.3 [M + Na]+.
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CHAPTER 4: OVERALL DISCUSSION OF DISSERTATION
Introduction

The two projects discussed in this dissertation deal with the development of novel
antimicrobial agents. These projects play a vital role in the need for continuing research
into ways to help combat the ever increasing rise of bacterial resistance. As bacteria
continue to evolve new resistant mechanisms, every piece of research into the
development of new ways to treat bacterial infections becomes crucial. The projects I
have worked on both involved bacteria, but each focused on a different type of bacteria.
The first project I worked on focused on new ways to treat infections caused by
Mycobacterium tuberculosis. The threat caused by the bacteria is growing, and
discovering novel agents with novel mechanisms of action is becoming a very high
priority among the scientific community. My second project involved the design of novel
treatment for gram-negative bacterial infections. These organisms are becoming
increasingly resistant to the antibiotics that are currently on the market, and therefore new
agents are desperately needed. The pipeline for combating these agents is sparse, and
more focus needs to be placed on this area by the pharmaceutical industry. The purpose
of this chapter is to provide a look into the key aspects of each project and to discuss
potential future endeavors that can keep these projects fruitful.
Urea Project

This project was discussed in Chapter 2 of this dissertation. It dealt with the
discovery of novel agents to help combat the increasing threat of multi- and extensivelydrug resistant tuberculosis. The agents synthesized in this chapter all possess a novel
mechanism of action that can be exploited to avoid resistance associated with current
therapies for tuberculosis. This project originated through the use of a current medicinal
chemistry technique that allows for the discovery of a small number of active compounds
within a large collection of compounds called high-throughput screening. Through this
process, the hit compound was discovered and selected for further modification.
The modifications chosen for this compound centered on the idea of obtaining a
complete SAR for this series of compounds. The first modifications made to the hit
compound involved changing the bulky aliphatic moiety while keeping the
trifluorophenyl group constant. A variety of bulky aliphatic groups were chosen to
replace the adamantyl moiety. These modifications, for the most part, led to compounds
with activity that was comparable to the parent compound. The compounds that lost
activity were compounds that contained groups that were not a bulky as the original
adamantyl group.
The next set of modifications involved the changing of the trifluorophenyl moiety
for other aromatic rings while holding the adamantyl position constant. These
modifications seemed to all provide compounds with similar activity to the parent
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compound. All of the groups tested in this set appeared to be well tolerated as the worst
MIC for a compound in this set was 3.125 µg/mL.
The next modifications involved holding the adamantyl constant and replacing the
aromatic ring with various non-aromatic groups consisting primarily of alkyl chains with
varying lengths. The majority of these compounds showed poor activity. There were a
few exceptions that showed activity comparable to the parent compounds, but these are
not candidates for further evaluation due to their poor drugability.
Modifications were made that also involved changing both sides simultaneously
so that the only remaining identifier of the parent compound was the urea moiety. These
compounds showed activity similar to the parent compounds, but none produced activity
that was better than the parent compound.
In order to complete the SAR study, it was crucial to make modifications to the
urea moiety itself. This was done using the parent compound. The urea moiety was
modified four different ways; (1) the carbonyl oxygen was replaced with a sulfur to make
a thiourea, (2) one of the nitrogen atoms was replaced with an oxygen to form a
carbamate, (3) one hydrogen atom attached to one of the nitrogen atoms was replaced
with a methyl group, (4) both hydrogen atoms on the nitrogen atoms were replaced with
methyl groups. These modifications produced a very clear and well defined SAR
concerning the urea moiety. As the modifications progress, from the parent compound,
the activity incrementally decreases with each modification. Replacement of the oxygen
atom with sulfur decreased the MIC from 0.01 µg/mL to 0.8 µg/mL. This decrease
inactivity can possible be related to the fact that sulfur is a larger atom than oxygen and
this could disrupt parts of the hydrogen bonding network found in the active site.
Replacement of a nitrogen atom with oxygen and methylation of one nitrogen atom both
decreased the MIC to 6 µg/mL. This appears to be due to the loss of the hydrogen atom
as a hydrogen bond donor to amino acid residues within the active site. Finally,
methylation of both nitrogen atoms resulted in an MIC of 12 µg/mL. This is follows the
previously mentioned hypothesis in that both hydrogen bond donating hydrogen atoms
have now been replaced.
This project, while producing compounds with excellent activity against
Mycobacterium tuberculosis, is not without faults. The compounds that have been
submitted for in vivo efficacy testing have not shown favorable results. This is more than
likely due to the high lipophilicity of these compounds. The next generation of these
compounds should focus on reducing the lipophilicity of these compounds in an effort to
improve their in vivo efficacy. The lead compound for this series has been identified as
compound 36 in Table 2.3. The compounds in this table were synthesized in an effort to
reduce the lipophilicity of this series. However, the majority of the compounds
synthesized showed a decrease in activity and were not acceptable for further
optimization. Compound 36 retained respectable activity and is less lipohilic. It has
shown to be orally bioavailable.107,163
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This series of compounds is also riddled with another hindrance. There is a
human form of the epoxide hydrolase enzyme, and these compounds need to selectively
inhibit the Mycobacterium tuberculosis form of the enzyme without interfering with the
human enzyme. Compound 36 may help with the lipophilicity issues associated with
these compounds, but it is also a known human epoxide hydrolase inhibitor. The next
generation of these compounds will need to be modified in a way that selectivity for
Mycobacterium tuberculosis can be achieved. There have already been three general
scaffolds identified that will be the future direction of this project (Figure 4.1). The
continuation of this project is already underway by a fellow member of the Lee Lab, and
the results will be reported in due time.
Tetramic Acid Project

This project is discussed in Chapter 3 of this dissertation. This project is truly in
its infancy. I have undertaken a lot of literature study with this project in an effort to
fully understand the scope of this project. I also set out to synthesize a few final
compounds for this project, but ultimately I was unsuccessful in synthesizing a complete
siderophore antibacterial agent. Although, I was not able to fully complete the synthesis
of on the desired compounds, this project should remain a focus in the Lee Lab due to the
potential it presents.
The potential of this project to be high impact is evident from the literature
precedence seen during my searches. It is shown in the pre-clinical candidate,
BAL30072, that the idea of attaching a siderophore to an antibacterial agent in an effort
to increase its efficacy is a valid hypothesis. Also, the initial experiments done by our
collaborators at Northeastern University show that the iron chelated tetramic acid of the
quorum sensing molecule synthesized in Scheme 3.1 helps an unknown microorganism
grow more abundantly and may be used as a growth enhancer for unknown
microorganisms. This is postulated to be due to the fact that the microorganism is
utilizing the tetramic acid to aid in its uptake of iron from the environment. The novel
siderophore used in our laboratory, the tetramic acid core, has numerous points of
diversity which can allow us to alter the structural diversity of this moiety in order to
ensure optimal activity.
The possibilities for this project seem to really cover a wide spectrum. In my
synthetic attempts during this project I was attempting to connect the tetramic acid
molecule synthesized in Scheme 3.4 to a cephalosporin antibiotic (Figure 4.2) However,
this is just the beginning of the possibilities for this type of compound. The direction of
this project is ultimately to see improved efficacy of gram-negative agents so as to help
alleviate burden associated with gram-negative infections. It would be interesting to see
the change in activity associated with attaching this class of siderophore to a variety of
antibacterial agents.
It would be very interesting to see if by taking an agent that only shows activity
against gram-positive bacteria, then attaching this class of siderophore, you can impart
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gram-negative activity as well. Also, the idea of taking an agent that was initially
designed to be active against gram-negative bacteria, but showed no activity in vivo, and
attaching this class of siderophore to see if any gram-negative activity can be obtained.
One of the shortcomings of this project at this time is that I have not been able to
successfully synthesize a compound from which data can be extracted. Therefore, one of
the issues appears to be that the chemistry associated with coupling the tetramic acid
moiety and the antibiotic of choice is difficult. The yield obtained from the synthesis of
the tetramic acid compound is also low, and thus there is room for improvement in that
aspect. The development of new synthetic schemes should be a top priority as this
project progresses into the future in an effort to overcome these shortcomings. If these
issues can be overcome, or at least attenuated, then the future of this project appears to be
very fruitful for the discovery of novel antibacterial agents.
Final Thoughts

During my tenure in graduate school, I have had the pleasure of being able to
conduct cutting edge research in an area that shows a clear need for new development.
Although my training has been as a synthetic chemist, my educational experience has
allowed me to become a well-rounded scientist. The idea of being more than just a
chemist is what initially attracted me to the field of medicinal chemistry. I realized that I
wanted to be in a field where the implications of my research can be seen and understood
immediately. The fact that one day I can synthesize a compound in the laboratory, then
have it tested in an in vitro system, and then determine the next course of action really
shows how the field of medicinal chemistry can and has changed the way that bacterial
infections are treated.
Medicinal chemistry is a very interdisciplinary science. It utilizes knowledge
from a variety of scientific fields in order to effectively create a well-rounded scientist.
Working as a medicinal chemist involves working in an interdisciplinary environment
where collaboration is the key to success. Training as a medicinal chemist can differ
depending upon one’s experience and interests, but in the end a medicinal chemist is a
person who can bridge some of the gaps between chemistry and biology. This ability
makes a well-trained medicinal chemist an invaluable asset to any interdisciplinary
research team. Interdisciplinary training should be included as a requirement in all
science-based Ph.D. training. Such a concept would lead to a better understanding of the
overall connectivity of science between fields and ultimately produce more well-rounded
scientists.
The projects that I have worked on during my time in graduate school have been
projects that serve a purpose. They have afforded me ample hands-on experience in the
chemistry laboratory. I have had the opportunity to expand my knowledge base on a
variety of different synthetic techniques. In addition to my expanded chemistry
knowledge, I have been able to grow my knowledge on the biological significance for
these projects. These projects allowed me to build up a significant knowledge base on
80

the infectious agents associated with these projects; Mycobacterium tuberculosis and
gram-negative infections. The ability to work on projects that required me to expand my
knowledge has really benefited me in my quest to become a well-rounded scientist. It is
my goal to continue to grow my knowledge base for each project that I undertake during
my professional career.
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